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Infectious diseases remain one of the leading causes of death worldwide, despite the discovery of 
new and improvements on existing antibiotics. Bacteria are constantly developing sophisticated 
mechanisms of resisting the effects of antibiotics, this in turn has increased their pathogenicity 
and virulence. Drugs belonging to the beta-lactam class of antibiotics are most commonly 
prescribed as they display a broad-spectrum activity against both gram-positive and gram-
negative bacteria. Carbapenems which are a member of this class is regarded as the last line of 
defence against bacterial infections. Resistance to carbapenems is on the increase especially by 
bacterial strains that are capable of producing metallo-beta lactamase enzymes. 
Infections caused by carbapenem resistant Enterobacteriaceae are deadly especially those 
mediated by metallo beta-lactamases. Efforts are being made to synthesize compounds that can 
inhibit these enzymes. Thus far little progress has been made as a clinically available metallo 
beta-lactamase inhibitor has not yet emerged, hence the scourge of carbapenem resistant 
infections rages on.   Therefore, the main aim of this study was to evaluate the in vitro and in 
vivo activities of metal chelating agents NO3PY and NOTA as potential metallo beta-lactamase 
inhibitors against carbapenem resistant Enterobacteriaceae. 
The metal-chelating agents used in this study were NOTA and NO3PY. In vitro analysis was 
performed to determine the minimum inhibitory concentrations by broth microdilution of 
meropenem alone and when co-administered with the chelators against resistant bacterial strains. 
The strains used in this study were Escherichia coli NDM-1, Klebsiella pneumoniae 449, 
Escherichia coli IMP-1 and Enterobacter cloacae NDM-1. Time kill kinetics was also evaluated 
at graded concentrations of MIC, 1*MIC, 2*MIC, 4*MIC, 8*MIC and 16*MIC. For the in vivo 
pharmacokinetics were determined using LC-MS/MS analysis.  Forty-eight healthy male Balb/c 
mice were divided into two groups; meropenem+NO3PY group and meropenem+NOTA group. 
Both groups received intraperitoneal doses at 10 mg/kg of meropenem and the MBLIs. 
Thereafter, the in vivo efficacy of meropenem co-administered with NOTA (100 mg/kg each) in 
a murine thigh infection was determined.   
Both chelators were able to restore the efficacy of meropenem to a concentration as low as 0.06 
µg/ml. The time kill kinetics also showed that both compounds were able to significantly extend 
the killing time of meropenem. In vivo pharmacokinetic analysis revealed that NO3PY may not 
xiv 
 
be a suitable candidate for in vivo efficacy study as the MBLI was not bioavailable in plasma at 
10mg/kg. NOTA on the other hand was bioavailable at the same concentration as NO3PY. The 
former was able to potentiate the effect of meropenem in vivo in a murine thigh infection model. 
It was evident by a significant reduction of colony forming unit counts in groups treated with 
meropenem co-administered with NOTA when compared to infected controls  
Further preclinical work such as in vitro and in vivo cytotoxicity tests, post beta-lactamase 
inhibitor effects among others are recommended for NOTA to further ascertain its suitability as a 


















Worldwide, infectious diseases remain one of the major causes of death even with easy access to 
antibiotics [1]. In a global population of 6.2 billion, infectious diseases cause 15 million out of 
nearly 57 million total deaths annually [2]. Over the years, the discovery, design and 
administration of antibiotics had witnessed profound successes. In 1900, before the discovery of 
antibiotics, whenever a patient was diagnosed with systemic infectious disease, death was almost 
inevitable [3, 4]. Then, the three leading causes of deaths were pneumonia, tuberculosis and 
diarrhea. These diseases caused about one third of all deaths of which 40% were among children 
younger than five years (USDCL, 1909). The discovery of antibiotics changed the face of 
modern medicine as infections that claimed multitudes of lives in the past are now in check [6]. 
However, these successful therapies by antibiotics were short-lived as infectious organisms have 
developed various resistance mechanisms to antibacterial agents thereby resulting in the 
emergence of resistant infections with possession of new genes that exacerbate their virulence     
[7, 8, 9, 10]. 
The discoveries of antibiotics have dated back to the first decade of the 20
th
 century. The next 
section highlights the timeline of these discoveries. 
1.1 History of Antibiotic Discovery 
In 1909, Paul Erlirch discovered the first antibiotic; Salvarsan; a compound whose antibacterial 
activity is mediated by the oxidation of its arsenic-bonded species [11]. The discovery of other 





Figure 1. 1: History of antibiotic discovery. 
Carbapenem, a beta-lactam antibiotic discovered by the pharmaceutical company Merck was 
proposed to be the drug of last resort as it was able to combat infections caused by some bacteria 
that hitherto had resisted treatment by other beta-lactam drugs [12,13, 14,15]. Unfortunately, the 
potency of this drug class is under threat by multi drug resistant bacteria that are emerging 
continually [16]. Therefore, it has become expedient for research to be intensified in the 
development of newer and more efficacious antibiotics else the most basic infections can become 
fatal.  
The effects of antibiotics and the ways exert these on specific parts of their target, differ from 
one to the other, hence the next section and five subsequent sub-sections will review these 
various ways.  
1.2 Classification of Antibiotics According to their Function and Mechanism of Action 
Clinically employed antibiotics act selectively on bacteria without affecting host cells and 
tissues. This property makes them unique among all other drugs. Based on their function, 
antibiotics can either be; 
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1. Bacteriostatic: These classes of antibiotics function in inhibiting the growth of pathogenic 
bacteria, then allow the body to develop natural defenses e.g. immune system to finally eliminate 
the organism [18,19]. 
2. Bactericidal: These classes of antibiotics kill the pathogenic bacteria [18,19].   
Antibiotics have been further classified into five major classes based on their mechanism of 
action (Figure 1). These are cell wall synthesis inhibitors, DNA synthesis inhibitors, protein 
synthesis inhibitors, antimetabolite and membrane function compromisers. [20-27]   
1.2.1. Cell wall synthesis inhibitors 
Peptidoglycan is the principal component of the bacterial cell wall and it supports the 
maintenance of the cell shape [28,29]. It consists of alternating strands of glucosamine and 
muramic acid units crosslinked by short peptides usually pentapeptides. Two enzymes are 
principally responsible for the synthesis of peptidoglycan. (i) Carboxy-peptidases, cleave the 
terminal D-ala from the pentapeptide, releasing ATP and exposing the amino acid to be 
crosslinked. (ii) Transpeptidases, which performs the crosslinking reaction to the glycan 
backbone [30].  
Antibiotics that inhibit cell wall synthesis do so by inhibiting the transpeptidase enzyme. They 
act as false transpeptidase substrate by imitating the terminal D-ala of the pentapeptide [31,32]. 
Beta-lactams are commonly employed antibiotics worldwide [33,34]. Beta-lactam of clinical 














Example; Ampicillin [38] 
 
Monobactam: 
Example; Aztreonam [37]  
Cephalosporins 
Examples: cefoxitin [39] 
 
 
1.2.2 Inhibition of protein synthesis 
Proteins are very important in cellular structure and function [40]. Enzymes and hormones are 
crucial to bacterial cell structure, replication and survival are all proteins. Tetracyclines, 
aminoglycosides, macrolides, lincosamides, chloramphenicol, (Table 2) are all inhibitors of 
protein synthesis in the bacteria [41-44]. Protein synthesis is mediated by ribosomes and some 















1.2.3 DNA synthesis inhibitors  
Ciprofloxacin, nalidixic acid and norfloxacin (Table 3) are all examples of drugs that inhibit 
DNA synthesis [48-49]. The mechanism of action is the inhibition of some key enzymes in DNA 
replication and transcription, which are DNA polymerase, topoisomerases, gyrase, helicase and 
RNA polymerase [50-53].  This inhibition eventually causes cell death [54].      


















1.2.4 Disruption of metabolic pathways 
The general mechanism of this class of antibiotics is the disruption of folic acid metabolism [57]. 
Tetrahydrofolate is important in the synthesis of bacterial cell wall protein and nucleotides. The 
precursor of tetrahydrofolate is folic acid [58].  Bacteria synthesize their folic acid from para 
aminobenzoic acid (PABA). Sulfasalazine (Table 4) inhibits the enzyme responsible for the 
conversion of PABA to folic acid whereas Trimethoprim impedes the conversion of folic acid to 
tetrahydrofolate [59,60]. 









1.2.5 Membrane function compromisers 
The cytoplasmic membrane encompasses the bacterial cell [63].  It is responsible for the 
selective permeability of substances into the cell, maintenance of osmotic balance, active 
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transport among others [64]. Colistin, daptomycin], and nystatin (Table 5) are examples of 
antibiotics that compromise the membrane function [65-70]. These antibiotics bind to the 
bacterial membrane, disrupting its structure by making it more permeable. The increased 
permeability allows other compounds to enter the cells thereby affecting the osmotic balance that 
eventually leads to cell death [71].      









Myriads of factors have allowed bacteria to develop different means of resisting the effects of the 
different classes of antibiotics discussed above. This various mechanism will be examined in the 
next section.   
1.3 Mechanisms of Bacterial Resistance to Antibiotics 
Antimicrobial resistance has emerged as a grave problem affecting human and animal health. 
The Center for Disease Control and Prevention in the United States of America has declared 
antimicrobial resistance as the second – most significant threat to health in 2014 [73]. Yearly, in 
the European Union alone, WHO reports that Antimicrobial resistant infections incur no less 
than $1.5 billion in healthcare expenses [74]. It has also been projected that by 2050, 
antimicrobial resistant infections will cause 10 million deaths per annum, the largest number of 
this deaths will occur in Africa and Asia and the financial burden will rise to $100 trillion [75]. 
Name Structure 
 





The ability of bacteria to evade the effects of an antibiotic is called antibiotic resistance [76]. A 
bacterium is said to have become resistant if its growth fails to be inhibited in spite of the 
availability of an antibiotic at therapeutic levels [77]. Several factors have been implicated for 
the increase of antibiotic resistance few of which are: 
1. Use, overuse and misuse of antibiotics [78,79]. 
2. A large amount of the world‘s antibiotic has been used in the treatment of animals both 
nutritionally and therapeutically. The unchecked usage leads to the evolution of antibiotic 
resistant- bacteria in farm animals, which can then also be transferred to humans through 
the food chain [80]. 
3. Poor infection control practices [81].  
4. Poor sanitary practices 
5. Prolong hospital stay most especially in the intensive care units etc. [82]. 
The mechanism of antibiotic resistance is broadly classified as [83,84]:   
1. Intrinsic/ Natural Resistance 
2. Acquired Resistance 
1.3.1 Intrinsic resistance  
Some bacteria are naturally resistant to a specific class of antibiotic whether there has been a 
prior exposure to it or not [85]. This may be due to their structural composition such as the innate 
resistance of gram-negative bacteria to vancomycin, which is quite large to cross the outer 
membrane therefore, it is only used for the treatment of infections mediated by gram-positive 
organisms [86, 87]. Metronidazole needs an anaerobic environment to be activated to its active 
form; this property makes aerobic bacteria to be intrinsically resistant to metronidazole [88, 89].  
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1.3.2 Acquired resistance   
An organism is said to have acquired resistance when it is no longer susceptible to an antibiotic 
at clinically achievable concentrations [90]. There are different established ways by which 
resistance can be acquired by different bacteria. 
1. Blockage of the entry of the drug into the organism‘s cell altogether or availability at 
just limited concentrations. This is achieved by efflux pump increase and influx pump 
decrease [91,92]. 
2. Target site modification, alteration or elimination [93]. 
3. Resistant gene acquisition [94]. 
4. Enzymatic inactivation of the drug [95] 
1.3.2.1 Increase in the expression of efflux pumps 
Efflux pumps function in the transportation of substances from inside the cell to the outside 
environment. Most of the substances they extrude are toxic wastes and antibiotics [96]. Some of 
these pumps are specific for one antibiotic while others can extrude different classes of 
antibiotics with the latter being a very strong factor in multidrug resistance [97]. Mutation in any 
of the regulatory proteins can lead to over-expression of these pumps consequently leading to a 
decreased concentration of the antibiotic intracellularly [98].  
1.3.2.2 Target site modification, alteration and elimination 
The target molecule that an antibiotic bind to in the bacterial cell is normally very specific [99]. 
A little modification in the target molecule will therefore affect the binding of an antibiotic to it. 
Some bacteria have found a way around this by genetically mutating their target site without 
altering cellular functions [93]. For example, beta-lactam antibiotics interact specifically with 
penicillin binding proteins (PBPs) in Streptococcus pneumonia. Alteration in the structure of the 
PBPs most especially PBP2b leads to decreased affinity to beta lactam antibiotics consequently 
giving rise to resistance [100-102].  
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1.3.2.3 Resistant gene acquisition   
Point mutations, gene rearrangements or deletions are the main genetic mechanism by which 
bacteria acquire resistance [103]. These resistance- causing mutations may not only be 
transferred to daughter cells (vertical gene transfer) but also between species (horizontal gene 
transfer) [104]. Horizontal gene transfer can either occur through any of these mechanisms: 
Bacterial Transduction, Conjugation or Transformation [105-108]. 
1.3.2.4 Enzymatic inactivation of the drug 
The production of a hydrolyzing enzyme called beta-lactamase is the principal mode of 
resistance to beta-lactam antibiotics [109]. They are produced by Enterobacter sp., Heamophilus 
sp., Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus etc. [110] and they all 
vary in their activity spectrum. The mechanism of action and classification of beta-lactamases 
will be discussed in the next two sub-sections.  
1.3.3. Mechanism of Action of Beta-lactamases 
When beta-lactamase binds to a beta-lactam, the serine/zinc in the active site of the beta-
lactamase forms a covalent bond with the beta lactam leading to the opening of the beta-lactam 
ring [111]. Hydrolysis of the covalent bond occurs by the introduction of an activated water 
molecule into the bond [112]. The result is that the beta-lactam antibiotic gets inactivated 
whereas, the beta lactamase is fully recovered and functional [113]. 
1.3.3.1. Classification of beta lactamases 
Ambler classification is most commonly used in classifying beta-lactamases structurally [114]. 
According to the amino acid sequence, Ambler grouped beta-lactamases into four classes, which 
are: A, B, C and D. Classes A, C and D have serine on their active site [114]. The serine residue 
is a nucleophilic agent that attacks the beta-lactam ring eventually forming a covalent acyl 
enzyme adduct [115]. Class C is also known as ‗AmpC‘ beta-lactamases [116] and class D as 
OXA beta-lactamases [117]. Class B has a divalent zinc ion in their active site, which when 
coordinates to an activated water molecule that produces a nucleophile facilitating the hydrolysis 
of the beta-lactam ring [118,119]. They are known as metallo beta-lactamases. Metallo beta-
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lactamases or Class B carbapenemases can hydrolyze almost all the beta-lactam drugs except 
monobactams [120]. Hitherto, they were not thought to constitute serious problems because they 
were mainly expressed by non-pathogenic bacteria [121,122] but with time, widespread invasion 
of gram negative pathogens occurred [123,124]. Based on their amino acid sequence, MBLs are 
divided into three sub-classes (B1, B2 B3) [125]. Sub-class B1 contains the largest number of 
MBLs of clinical importance, they include IMP-1 [126], VIM-2 [127], VIM-7 [128], NDM-1 
[129,130]. Enterobacteriaceae producing NDM-1 cause infections such as septicemia, 
pulmonary infections, peritonitis etc. [131,132]. It was first isolated from a Swedish patient who 
had been hospitalized in New Delhi, India [133]. Over the years, the spread of beta-lactamases 
have necessitated different steps to be taken to stem its menace. If successful, the world‘s 
antibiotics arsenal will be preserved. 
1.4 Combatting Beta- Lactamase Mediated Resistance 
In combating antimicrobial resistance mediated by beta-lactamases, two approaches have been in 
operation. (i) Modification of the structure of the available beta-lactam drugs, so that this 
alteration will prevent hydrolysis of antibiotic drugs by beta-lactamases [112]. (ii) Co-
administration of beta-lactam drugs with beta-lactamase inhibitors [134]. The inhibitor acts as a 
protector of the beta-lactam drug [112]. It inhibits the beta-lactamase enzymes (serine and zinc) 
consequently allowing the normal action of the beta-lactam drug. The next and subsequent sub-
sections will dissert both the different classes of beta-lactamase inhibitors. 
1.4.1 Serine beta-lactamase inhibitors 
Clavulanic acid, Sulbactam and Tazobactam  are beta-lactamase inhibitors, which have structural 
similarity to penicillins [135-138] (Table 6). They are the earliest discovered inhibitors before 
the advent of new ones. Clavulanic acid was isolated from Streptomyces clavuligenus [139]. 
When combined with beta-lactam drugs, it successfully inhibits the growth of class A beta-
lactamase producing organisms [140]. Sulbactam and tazobactam are penicillanic acid sulfones 
synthesized in 1978 and 1980 respectively [136,137].  Sulbactam inhibits class A beta-lactamase 
producing organisms but not as strongly as clavulanic acid and tazobactam [141]. Generally, all 
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this class of inhibitors are very effective against class A beta-lactamase but quite weak in 
inhibiting class C and D beta lactamases [142-144]. 













Clavulanic acid, sulbactam and tazobactam are traditional serine beta-lactamase inhibitors. In 
recent times other inhibitors that do not have a beta-lactam ring as their core have been 
discovered.  Three of which are discussed next. 
1.4.2. Newer serine beta lactamase inhibitors 
1.4.2.1. Avibactam 
Avibactam (Table 7) is a non-beta lactam-beta lactamase inhibitor belonging to the 
diazabicyclooctane family whose mechanism of inhibition is mediated by reactive urea [146-
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147]. It is active against beta lactamases of Ambler class A (ESBL and KPC), class C (AmpC) 
and some of the class D group (OXA-48) [148,149]. Avibactam is a reversible inhibitor with a 
half-life of 16 min for TEM-1 beta–lactamase [146]. It is not an inducer of beta-lactamase 
production unlike clavulanic acid, tazobactam and sulbactam [149]. 







1.4.2.2. Varbobactam (formerly known as RPX7009) 
Prior to this period boronic acid has been known to be a very efficient inhibitor of serine- beta 
lactamase [151]. Like avibactam, varbobactam is a non-beta lactam beta-lactamase inhibitor but 
with a boronic acid core (Table 8) [152]. It is able to inhibit Ambler class A and C enzymes but 
not class B metallo-beta-lactamase [152]. Meropenem when co-administered with varbobatam in 
vitro elicited potent activity against multi-drug resistant carbapenemase producing strain of 













1.4.2.3.  Relebactam 
Relebactam (Table 9) formerly known as MK-7655, is known for its broad-spectrum activity 
against class A and C beta-lactamase inhibitors and KPC-producing strains [154]. It has a 
remarkable similarity to avibactam in terms of activity [153]. The effects of its co-administration 
with imipenem and cilastatin are still being investigated clinically [155].   






There are also various synthetic compounds that have been tested as potential inhibitors for class 
B beta-lactamases (metallo beta-lactamase). They are examined in the next section. 
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1.4.3 Some metallo-beta lactamase inhibitors 
 Thiol-based Inhibitors 
Metallo-beta-lactamase inhibitors potentiate their activity through their zinc moiety [114]. Sulfur 
has a good affinity for zinc and this property has been exploited in designing thiol-based 
inhibitors [156] (Table 10). A library of mercaptoacetic thiol esters have been synthesized and 
tested against several MBLs. It was discovered to restore the efficacy of beta-lactams [157-159].  
Table 1. 10: Structure of some thiol-based metallo-beta lactamase inhibitors 




















Peptide and pyridine dicarboxylates 
N-carbobenzoxy-D-cysteinyl-D-phenylalanine [126] (Table 11) elicited a remarkable activity 
against MBL-producing B. cereus [161]. Dithioacid was also reported to be active against MBL-
producing B. fragilis and S. maltophilia [162].   










Calcium EDTA (Ca-EDTA) 
EDTA, though a very active metal-chelator with antimicrobial activity has a limited use 
clinically due to its toxicity [164]. However, Calcium-disodium EDTA (Ca-EDTA) exhibit 
minimal toxicity and has been approved for treating lead poisoning [165,166]. Ca-EDTA is very 
active against MBLs such as IMP-1, VIM-2 and NDM-1 [167,168]. However, the potential 
toxicity of Ca-EDTA includes nephrotoxicity, neurotoxicity and hypocalcemia [167]. 
The various potential  metallo beta-lactamase reviewed above have their limitations, hence 




1.5 Why is Carbapenem Resistance a Significant Health Problem? 
Enterobacteriaceae is a large family of gram-negative bacteria, which are normal resident of the 
human intestinal flora [169]. They can become pathogenic, causing infections such as 
meningitis, septicemia, pneumonia [170] etc. Examples of bacteria belonging to this class 
include: E. coli, K. pneumoniae,Salmonella, Shigella [170] etc. Enterobacteriaceae are also 
prime factors in causing health-care related (nosocomial) infections such as bloodstream bladder, 
lungs and skin infections [171-173]. Enterobacteriaceae can become carbapenem resistant in 
patients exposed to long hospital stay especially in intensive care units, transfer from one health-
care facility to another, usage of in-dwelling catheter, mechanical ventilation etc [174]. The 
Center for Disease Control also classified Carbapenem resistant Enterobacteriaceae (CRE) as 
any bacteria belonging to the Enterbactriaceae family with a susceptibility to etrapenem ≥ 
2mg/ml or ≥4mg/ml to meropenem, imipenem and doripenem [175]. Infections caused by CREs 
have contributed significantly to the morbidity and mortality rate worldwide [176]. A report by 
China-based Antibiotic Resistance Surveillance ―The CHINET‖, reveals that majority of cases of 
CRE infections is caused by K.pneumoniae,which is resistant to both imipenem and meropenem 
[177].  The employment of carbapenems for the treatment of these infections is now being 
threatened due to the production of carbapenem hydrolyzing enzymes by this group of bacteria. 
South Africa as a country has not been spared from the escalating menace of infection caused by 
CREs. In a comprehensive review of the current state of resistance to antibiotics of last resort in 
South Africa, Sekyere revealed that out of 2315 cases of carbapenem resistant infections reported 
between January 2000 and May 20 2016, 1,220 cases were from Guateng and this constituted the 
majority followed by the 515 cases from KwaZulu-Natal [178]. The most common resistant 
isolate identified was Klebsiella pneumonia while the most described carbapenemase was New 
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Delhi Metallo beta-lactamase (NDM) followed by OXA-48 [178]. Several studies have further 
documented that many South Africans who contract infections caused by CREs eventually die 
[179-181]. 
Inhibitors for other classes of beta-lactamases are clinically and commercially available as earlier 
reviewed. A challenge still remains for the design of compounds that will effectively inhibit class 
B cabapenemases (metallo-beta lactamase). None of the potential metallo-beta lactamases earlier 
mentioned has made it to the clinical stage as they can only inhibit the metallo-beta lactamases in 
vitro. This may be due to the toxicity of the compounds, its non-bioavailability among other 
factors. In stemming the scourge of infections mediated by metallo beta-lactamase producing 
bacteria, this study is aimed at exploring some bi-functional chelating agents (BFCAs) as 
potential metallo beta-lactamase inhibitors in vitro and most especially in vivo. 
1.6. Bifunctional Chelating Agents 
Bi-functional chelating agents (BFCAs) are very vital in their use for radio-imaging and 
radiotherapy [182]. BFCAs have been used in complexing radionuclides/small metal ions with 

















Lu for single photon emission 
computed tomography (SPECT) [183,184]. These metal ions are conveyed to tumor sites by 
targeted therapy. It is assumed that given its function of chelating metal ions, it will be able to 
chelate Zn
2+ 
that are employed by metallo-beta lactamases facilitating the hydrolysis of beta-
lactams.  Complexation of the chelator will inhibit the activity of the metallo-beta lactamase, 
thereby restoring the efficacy of carbapenems. In this study, two macrocyclic BFCAs were 
investigated in order to determine if they will effectively inhibit metallo-beta lactamase in vitro 
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and in vivo. The chelating agents were 1,4,7-triazacyclononane-1,4,7 triacetic acid (NOTA) and 
1,4,7-Tris(2-picolinyl)-1,4,7-triazacyclononane (NO3PY) [185-186] (Table 12). NOTA has been 
studied extensively and it is regarded as one of the best chelators for radiocopper owing to the 
high stability with which it binds radionuclides and its commercial availability [187]. NO3PY 
like NOTA, exhibits high stability when in reducing conditions and rapid complexation with 
radionuclides [188]. NO3PY was synthesized by the Catalysis and Peptide research Unit of the 
University of KwaZulu Natal, Westville, Durban, South Africa for the purpose of this study  










To determine the in vitro and in vivo efficacy of both metal chelating agents as potential metallo 
beta-lactamase, the methodology examined in the next section was employed. 
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1.7. Analytical and Biophysical Techniques for Measuring In vitro And In vivo Efficacy 
1.7.1. Synergy Testing and Time Kill Kinetics 
One of the strategies to combat the growing trend of antibiotic resistance is the application of 
drug combinations [189-191].  There are several ways in which two or more test drug can 
interact when co-administered, the effect can either be synergistic/ additive, or antagonistic and 
suppressive [192]. Synergy means that the activities of both compounds are improved when co-
administered compared to their individual effects. Drug combination/ interaction is not only 
limited to two drugs or antibiotics, it can be between an antibiotic and a compound that has no 
antibacterial activity such as an inhibitor of beta lactamases [193]. Here, the synergistic 
mechanism is such that the inhibitor inactivates the antibiotic hydrolyzing enzymes thereby 
allowing the antibiotic to work normally. The checkerboard method or fractional inhibitory 
concentration (FIC) [194] is used in measuring the effects of drug combination [195,196]. Its 
methodology is very similar to that used in determining minimum inhibitory concentration 
(MIC). 
The FIC for a drug is the minimal inhibitory concentration (MIC) of the drug in combination 
divided by the MIC of the drug used alone. If the FIC index is ≤ 0.5, the antibiotic combination 
is interpreted as being synergistic; FIC index >0.5 and ≤1.0 as additive, between 1 and 4 as 
indifferent and > 4 as antagonistic [197-198]. 
Time-kill kinetics is a pharmacological function used to evaluate the rate at which different 
concentrations of antibiotics reduces bacterial growth over a period of time [199]. It can be used 
to determine whether the different classes of antibiotics exert their effects in a time-dependent or 
a concentration-dependent manner [200]. In vitro time kill-kinetics gives information about 
dosing intervals [201]. It involves incubating a specific density of bacterial inoculum with a 
known concentration of antibiotic and monitoring the rate at which the antibiotic kills the 
bacteria per unit time [199]. Determining the efficacy of potential beta-lactamase inhibitor can be 
taken a step further by evaluating if such inhibitor will be able to restore the efficacy of 




1.7.2. Murine Thigh Infection Model. 
In vivo efficacy testing is very crucial in drug research. It is a bridge that links the in vitro 
susceptibility test and clinical trials. As the basis of clinical trials, combination therapies or an 
entirely new drug must be evaluated in animal models [202,203].  One of its many advantages is 
that it allows individual effects to be monitored separately when certain parameters are varied 
[204]. The limitation however is the difference in the pharmacokinetic profiles of animal and 
actual human subjects. The rate of drug elimination is much faster in animals than humans 
[205,206]. 
Murine thigh infection model represents an uncomplicated, sensitive and highly reproducible 
approach for evaluating the in vivo efficacy of a drug while measuring at the same time, the drug 
pharmacokinetics either in the plasma or in the tissue of the infected animals [205,207]. In the 
1940s, the first murine thigh infection as used by Eagle and his associate to evaluate the effects 
of penicillin on Streptococcus growth [208]. This model was then improved upon by Craig and 
his co-workers in the 1970s. The improvement involves suppressing the immune system of the 
mice by making them neutropenic before the introduction of the bacterial inoculum [209,210]. 
Induction of neutropenia involves the administration of immunosuppressant drug at 150mg/kg 





 cfu can be inoculated into the mice thigh. 
For a single dose study, after two hours of inoculating the mice (ideally, at this time the organism 
will be in the logarithm growth phase), 0.2ml of a known concentration of antibiotic is 
administered. Animals can then be euthanized at different time points for the collection of blood 
and thigh removal. The viable bacterial cell count of the treated mice thigh is evaluated and 
compared with that of infected control [207]. Infection by different microorganisms have been 
studied using this model e.g. Pseudomonas aeruginosa, Enterobacter cloacae, Escherichia coli, 
K.  pneumoniae among others. 
It is important to determine the in vivo bioavailabity and pharmacokinetic parameters of any 
potential drug candidate. This will give an insight into its half-life, LC50, Tmax among other 
important variables. Often times, the Liquid-Chromatography Mass Spectrometry (LC-MS) is 
used to achieve this procedure.  
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1.7.3. Liquid Chromatography Mass-Spectrometry (LC-MS) 
Mass spectrometry is an analytical tool that enables the production of ions and the separation of 
it based on their charge to mass ratio [211,212]. Using this technique, analytes can be quantified 
and important information about their chemical composition is obtained [213-215]. Basically, it 
is made up of five parts, which are: sample introduction, ionization, mass analysis, ion detection, 
data treatment.  In principle, the analyte is introduced as a small quantity and admitted to the 
ionization source after chromatographic separation, which transforms it into ions. The resultant 
ions pass through the mass analyzer where they are separated according to their mass-to-charge 
ratio [216,217]. Lenses resident in the mass-analyzer focus the ions to the detector in the form of 
electrical signals. The electrical signals that reach the detector are directly proportional to the 
number of ions formed. There are several ionization techniques involved in mass spectrometry, 
which are classified as either hard or soft [218,219]. Example of a hard ionization technique is 
electron ionization [220,221]. Chemical ionization, atmospheric pressure chemical ionization and 
fast atom bombardment are all examples of soft ionization techniques. Electron spray ionization 
and matrix-assisted laser desorption ionization are examples of soft ionization techniques [222-
228]. 
Coupling of liquid chromatography, which is a type of chromatographic separation technique to 
mass spectrometry results in a powerful, sensitive, selective and high-speed analytical technique 
[229]. LC-MS has become a preferred tool for analyzing drugs and different metabolites. It 
allows more specific identification of a compound, which is impossible with liquid 
chromatography alone. Apart from the pharmacokinetic analysis of drugs, it is being used for the 
analysis of mixture of complex proteins, biological fluids (serum, urine etc) and natural products 
[230-233].  
1.8 Aims and Objectives of The Study 
The aim of this study is to evaluate the in vitro and in vivo efficacy of metal chelating (NO3PY  




SPECIFIC OBJECTIVES OF THE STUDY 
1. To pre-screen both compounds (NO3PY and NOTA) in vitro for antibacterial activity 
using the CLSI broth microdilution and checkerboard methods. The compounds are co-
administered with meropenem 
2. To develop a simple, sensitive, specific and reproducible LC-MS/MS method for the 
detection and quantification NO3PY and NOTA in different biological matrices. 
3. To quantify the in vivo bio-availability i.e. free concentrations of the compounds in the 
blood (i.e. plasma) at different time points. 
4. To determine if the compounds restore the efficacy of meropenem in vivo (Thigh 
infection in a murine model). 
5. To determine if plasma concentrations of meropenem co-administered with NO3PY and 
NOTA are above the MIC for Carbapenem resistant enterobacteriaceae 
1.8.1. Thesis Outline 
This thesis comprises of Chapter 1, which is an introduction and review on antibiotics, antibiotic 
resistance, metallo beta-lactamase inhibitors and techniques utilized herein. Chapter 2 presents 
the methodology involved to determine the in vitro and in vivo activities of the NO3PY and 
NOTA as inhibitors against metallo beta lactamase producing enzymes. The results obtained in 
this chapter were submitted for publication in a high impact factor journal (International Journal 
of Antimicrobial Agent. Impact Factor: 4.253). Chapter 3 concludes the thesis and provides 






[1] WHO. World Health Organization. Global Health Estimates 2016: Deaths by Cause, Age, 
Sex, by Country and by Region, 2000-2016. Geneva, 2018. 
[2] WHO. World Health Organization. The World Health Report 2007—a safer future: global 
public health in the 21st Century, 2007 [Accessed: Sept 15, 2008]. 
http://www.who.int/whr/2007/en/index.html  
[3] Weiting-Pascha. Gulhane Festchrift., Leipzig., George Thieme., 1909. 
[4] Noyan A. My battle with outbreaks In: recent war (In Turkish), Ankara: Ankara Medical 
Facility Publication, 1956. 
[5] USDCL. Department of Commerce and Labor, Bureau of the Census. Mortality Statistics, 
1900 to 1904. Washington, DC: US Department of Commerce and Labor, 1906. 
[6] WHO. World Health Organization. Antimicrobial resistance: global report on surveillance, 
2014. France: World Health Organization. 
[7] Lin J, Nishino K, Roberts MC, Tolmasky M, Aminov RI, Zhang L. Mechanisms of antibiotic 
resistance. Front Microbiol 2015;6:34. 
[8] Chastre J, Trouillet JL. Problem  pathogens (Pseudomonas aeruginosa and Acinetobacter). 
Semin Respir Infect 2000;15:287-98.2.  
[9] Hanberger H, Diekema D, Fluit A, Jones R, Struelens M, Spencer R, et al. Surveillance of 
antibiotics resistance in European ICUs. J Hosp Infect 200;48:161-176.  
[10] Jones RN. Resistance patterns among nosocomial pathogens: Trends over the past few 
years. Chest 2001;119:397S-404. 
[11] Lloyd NC, Morgan HW, Nicholson BK, Ronimus RS. The composition of Ehrlich‘s 
salvarsan: resolution of a century-old debate. Angew Chem Int Ed Engl 2005;44:941–944 
25 
 
[12] Birnbaum J, Kahan FM, Kropp H, MacDonald JS. Carbapenems, a new class of beta-lactam 
antibiotics. Discovery and development of imipenem/cilastatin. Am J Med 1985;78(6A):3–21. 
[13] Sneader W. Drug Discovery-A History. Wiley, 2006. pp. 310. ISBN 978-0-471-89980-8.  
[14] Torres JA, Villegas MV, Quinn JP. Current concepts in antibiotic-resistant gram-negative 
bacteria. Exp Rev AntiInfect Ther 2007;5:833–43 
[15] Bradley JS. et al. Carbapenems in clinical practice: a guide to their use in serious infection. 
Int J Antimicrob Agts 1999;11:93–100 
[16] Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 
2007;20:440–58. 
[17] Lietman PS. What is an antibiotic? The Journal of Pediatrics, 1986;108(5):824–29. 
[18] Wilson G, Miles A. Topley and Wilson's principles of bacteriology and immunity, 5th ed., 
1964. Edward Arnold, London, United Kingdom 
[19] Walsh C. Antibiotics: actions, origins, resistance. 1st Ed., pp. 345; 2003. ASM Press, 
Washington, DC.  
[20] Heesemann J. Mechanisms of resistance to beta-lactam antibiotics. Infect 1993;21(1):S4-9. 
[21] Chen CR, Malik M, Snyder M, Drlica K. DNA gyrase and topoisomerase IV on the 
bacterial chromosome: quinolone – induced DNA cleavage. J Mol Biol 1996;258:627-37 
[22] Menninger JR, Otto DP. Erythromycin, carbomycin, and spiramycin inhibit protein 
synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes. Antimicrob Agts 
Chem 1982;21:811-18. 




[24] Patel U, Yan YP, Hobbs FWJr, Kaczmarczyk J, Slee AM, Pompliano DL, Kurilla MG, 
Bobkova EV. Oxazolidinones mechanism of action: Inhibition of the first peptide bond 
formation. J Biol Chem 2001;276(40):37199-205.  
[25] Talaro KP, Chess B. Foundations in microbiology. 8th Ed., 2008. McGraw Hill, New York 
[26] Alborn WE, Allen JrNE, Preston DA. Daptomycin distrupts membrane potential in growing 
Staphylococcus aureus. Antimicrob Agts Chem 1991;35(11):2282-7  
[27] Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of 
multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005;40:1333–41. 
doi:10.1086/429323. 
[28] Lawrence PJ, Strominger JL. Biosynthesis of the peptidoglycan of bacterial cell walls. The J 
Biol Chem 1970;245(14):3660-6 
[29] Lerner TR, Lovering AL, Bui NK, Uchida K, Aizawa S-I, Vollmer W, Sockett RE. 
Specialized peptidoglycan hydrolases sculpt the intra-bacterial niche of predatory bdellovibrio 
and increase population fitness. PLoS Path 2012;8(2):e1002524 
[30] Strominger JL. Penicillin-sensitive enzymatic reactions in bacterial cell wall synthesis. 
Harvey Lect 1966;64:179-214. 
[31] Wise EM, Park JT. Penicillin: its basic site of action as an inhibitor of a peptide cross-
linking reaction in cell wall mucopeptide synthesis. Proc Natl Acad Sci USA 1965;54(1):75-81. 
[32] Tipper DJ, Strominger JL. Mechanism of action of penicillins: a proposal based on their 
structural similarity to acyl-D-alanyl-D-alanine. Proc Natl Acad Sci USA 1965;54:1133-41. 
[33] Livermore DM. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and 
Acinetobacter. Trends Microbiol 2006;14:413–20. 
[34] Livermore DM. Fourteen years in resistance. Int. J. Antimicrob Chem 2012;39:283–94. 
[35] Abraham EP, Newton GGF. The structure of cephalosporin C. Biochem J 1961;79:377-93. 
27 
 
[36] Kahan FM, Kropp H, Sundelof JG, Birnbaum J. Thienamycin: development of imipenem-
cilastatin. J Antimicrob Chem 1983;12:1-35. 
[37] Duma RJ. Aztreonam, the First Monobactam. Ann Intern Med 1987;106:766–67. 
[38] Ravina E. The evolution of drug discovery from traditional medicines to modern drugs (1 
ed.). Weinheim: Wiley-VCH. p. 262., 2011. ISBN 9783527326693 
[39] Gootz TD. Discovery and development of new antimicrobial agents. Clin Microbiol Rev 
1990;3(1):13–31.  
[40] Berg JM, Tymoczko JL, Stryer L.Biochemistry. 5th edition. New York: W H Freeman; 
2002. 
[41] Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular 
biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65(2):232-60.  
[42] Jana S, Deb JK. Molecular understanding of aminoglycoside action and resistance. Appl 
Microbiol Biotech 2006;70(2):140-50.  
[43] Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J 
Antimicrobial Chemo 1993;31(Suppl. C):1-9.  
[44] Feder HM-Jr, Osier C, Maderazo EG. Chloramphenicol: A review of its use in clinical 
practice. Rev Inf Dis 1981;3(3):479-91.  
[45] Tenson T, Mankin A. Antibiotics and the ribosome. Mol Microbiol 2006;59(6): 1664–77. 
[46] Connover LH, Moreland WT, English AR. et al. Terramycin. XI. Tetracycline. J Am Chem 
Soc 1953;75:5455. 
[47] Pongs O. Chapter 3: Chloramphenicol. In Hahn, eFred E. Mechanism of action of 
antibacterial agents. Antibiotics Volume V Part 1. Berlin, Heidelberg: Springer Berlin 
Heidelberg. pp. 26–42., 1979. ISBN 978-3-642-46403-4. 
28 
 
[48] Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ. A 
critical review of the fluoroquinolones: focus on respiratory infections. Drug 2002;62(1):13-59 
[49] Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chem 
2003;51(Suppl. 1):1-11.  
[50] Gellert M, Mizuuchi K, O'Dea MH, Nash HA. DNA gyrase: an enzyme that introduces 
superhelical turns into DNA. Proc Natl Acad Sci USA 1976;73:3872–76. 
[51] Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4‐ quinolones. Microbiol Mol 
Biol Rev 1997;61:377–92. 
[52] Hiasa, H. The Glu‐ 84 of the parC subunit plays critical roles in both Topoisomerase IV‐
quinolone and Topoisomerase IV–DNA interactions. Biochemistry 2002;41:11779–85. 
[53] Vila J. Fluoroquinolone resistance. In: Front Antimicrob Resíst: A Tribute to Stuart B. 
Levy. White, D.G., Alekshun, M.N., and McDermott, P.F. (eds). Washington, DC, USA: ASM 
Press, pp. 41–52, 2005. 
[54] Bearden DT, Danziger LH. (2001). Mechanism of action of and resistance to quinolones. 
Pharmacother 2001;21(10 Pt. 2):224S–232S.  
[55] Torok E, Ed Moran, Cooke F. Oxford Handbook of Infectious Diseases and Microbiology. 
OUP Oxford. 2009. p. 56. ISBN 978-0-19-103962-1. 
[56] Wise R, Andrews JM, Edwards LJ. In vitro activity of Bay 09867, a new quinoline 
derivative, compared with those of other antimicrobial agents. Antimicrob Agts Chemother 
1983;23(4):559–64. 
[57] Neu HC, Gootz TD, Baron S. Medical Microbiology. 4th edition. Galveston (TX), 1996. 
University of Texas Medical Branch at Galveston. 
[58] Hitchings GH. Mechanism of Action of Trimethoprim-Sulfamethoxazole--I. The J Infect 
Dis 1973;128(Supp. 3):S433-S436.    
[59] Connor EE. Sulfonamide antibiotics. Primary Care Update for OB/GYNS, 1998;5(1):32–5.  
29 
 
[60] Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim-sulfamethoxazole 
revisted. Arch Intern Med 2003;163(4):402-10.    
[61] Svartz N. Salazopyrin, a new sulfanilamide preparation. A. therapeutic results in rheumatic 
polyarthritis. B. erapeutic results in ulcerative colitis. Toxic manifestations in treatment with 
sulphanilamide preparations. Acta Med Scand 1942;110:577-98. 
[62] Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 2001;32(11): 
1608–14. 
[63] Hughes DE. The bacterial cytoplasmic membrane. J Gm Microbiol 1962;29:39-46.  
[64] Alberts B, Johnson A, Lewis J. et al. Molecular Biology of the Cell (4th ed.). New York: 
Garland Science, 2002. ISBN 978-0-8153-3218-3.  
[65] Koyama Y, Kurosasa A, Tsuchiya A, Takakuta A. A new antibiotic 'colistin' produced by 
spore-forming soil bacteria. J Antibiot 1950;3:457e8 
[66] Charles PG, Grayson ML. The dearth of new antibiotic development: why we should be 
worried and what we can do about it. The Med J Aust 2004;181 (10):549–53. 
[67] Gupte M, Kulkarni P, Ganguli BN. Antifungal antibiotics. Appl Microbiol Biotechnol 
2002;58(1):46–57. 
[68] Dixon RA, Chopra I. Leakage of periplasmic proteins from Escherichia coli mediated by 
polymyxin B nonapeptide. Antimicrob Agts Chemother 1986;29:781–88. 
doi:10.1128/AAC.29.5.781 
[69] Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: 
the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet 
Infect Dis 2006;6:589–601. 
[70] Falagas ME, Matthaiou DK, Bliziotis IAJ. The role of aminoglycosides in combination with 
a beta‐ lactam for the treatment of bacterial endocarditis: a meta‐ analysis of comparative trials. 
J Antimicrob Chemother 2006;57:639–647.  
30 
 
[71] Peterson JW, Baron S. Bacterial Pathogenesis. Medical Microbiology. 4th edition, 1996. 
Galveston (TX): University of Texas Medical Branch at Galveston. 
[72] Espinel-Ingroff AV. Medical Mycology in the United States a Historical Analysis (1894-
1996). Dordrecht: Springer Netherlands. p. 62, 2013. ISBN 9789401703116.  
[73] CDC. Mission: Critical. In: Centers for Disease Control and Prevention, 2014. Retrieved 
from http://www.cdc.gov/media/releases/2014/p1215-2014-year-in-review.html 
[74] ECDC. European Centre for Disease Prevention and Control, European Medicines Agency. 
The bacterial challenge: time to react. Stockholm, 2009. (EMEA/576176/2009; 
https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0909_TER_The_Bact
erial_Challenge_Time_to_React.pdf.   
[75] O‘Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations, 
2014.http://amrreview.org/sites/default/files/AMR%20Review%20Paper%20%20Tackling%20a
%20crisis%20for%20the%20health%20and%20wealth%20of%20nations 1.pdf 
[76] CDC. Antibiotic resistance questions and answers. Centers for Disease Control and 
Prevention, 2015a. Available from: http://www.cdc.gov/getsmart/antibiotic- use/antibiotic-
resistance-faqs.html 
[77] Levison ME. Overview of bacteria, 2015. Merck Manuals. Available from: 
http://www.merckmanuals.com/home/infections/bacterial_infections/overview_of_bacteria.html 
[78] CDC. Center for Disease Control and Prevention Antibiotic Resistance Threats in the 
United States, 2013a. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-
threats-2013-508.pdf. 
[79] CDC. Center for Disease Control and Prevention World Health Day: Media Fact Sheet, 
2013b. Available at: http://www.cdc.gov/media/releases/2011/f0407_antimicrobial 
resistance.pdf. 




[81] Ponce-de-Leon S. The needs of developing countries and the resources required. J Hosp 
Infect 1991;18(Suppl. A):376–81.  
[82] Vlahović-Palčevski V, Dumpis U, Mitt P, Gulbinovic ǰ, Struwe J, Palčevski G et al. 
Benchmarking antimicrobial drug use at university hospitals in five European countries. Clinical 
Microbiology and Infection 2007;13(3):277–83.  
[83] Fernandez L, Breidenstein EB, Hancock RE. Drug Resist Updat 2011;14:1–21. 
[84] Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Nat Rev Microbiol 
2015;13:42–51. 
[85] Olivares J, Bernardini A, Garcia-Leon G, Corona FB, Sanchez M, Martinez JL. The 
intrinsic resistome of bacterial pathogens. Front Microbiol 2013;4:103 
[86] Griffith RS. Introduction to vancomycin. Rev Infect Dis. 1981;3:200-4.  
[87] Vazquez-Guillamet C, Kollef MH. Treatment of gram-positive infections in critically ill 
patients. BMC Infect Dis 2014;14:92. 
[88] Tally FP, Sullivan CE. Metronidazole: in vitro activity, pharmacology and efficacy in 
anaerobic bacterial infections. Pharmacother 1981;1(1):28-38. 
[89] Abebe E, Tegegne B, Tibebu S. A review on molecular mechanisms of bacterial resistance 
to antibiotics. European J Appl Sci 2016;8(5): 301-310. 
[90] Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents, epidemiology, 
molecular mechanisms and clinical management. Infect. Dis. Clin. North Am. 1995;9:497–530. 
[91] Langton KP, Henderson PJ, Herbert RB. Antibiotic resistance: multidrug efflux proteins, a 
common transport mechanism? Nat Prod Rep 2005;22:439-451. 
[92] Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbial. 
Mol Biol Rev 2003;67(4):593-656 
32 
 
[93] Lambert PA. Bacterial resistance to antibiotics: modified target sites. Adv Drug Deliv Rev 
2005;57: 1471-1485.  
[94] Roberts MC. Update on acquired Tetracycline resistance genes. FEMS Microbio Lett 
2005;245:195-203. 
[95] Poole K. Resistance to beta-lactam antibiotics. Cell Mol Life Sci 2004;61:2200-23. 
Protocols. New York: CRC Press 
[96] Pearson JP, Van Delden C, Iglewski BH. Active efflux and diffusion are involved in 
transport of Pseudomonas aeruginosa cell-to-cell signals. J Bacteriol. 1999;181:1203–10 
[97] Giedraitien A, Vitkauskien A, Naginien R, Pavilonis A. Antibiotic resistance mechanisms of 
clinically important bacteria. Medicin 2011;47(3):137–146 
[98] Sun J, Deng Z, Yan A. Bacterial multidrug efflux pumps: Mechanisms, physiology and 
pharmacological exploitations. Biochem Biophys Res Comm 2014;453(2):254–67.  
[99] Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to 
networks. Nat Rev Microbiol 2010;8(6):423–35. 
[100] du Plessis M, Bingen E, Klugman KP. Analysis of penicillin-binding proteins genes of 
clinical isolates of Streptococcus pneumoniae with reduced susceptibility to amoxicillin. 
Antimicrob Agts Chemo 2002;46:2349–57.  
[101] Grebe T, Hakenbeck R. Penicillin-binding proteins 2b and 2x of Streptococcus 
pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics, 
Antimicrob Agt Chem 1996;40:829–34. 
[102] Kosowska K, Jacobs MR, Bajaksouzian S, Koeth L, Appelbaum PC. Alterations of 
penicillin-binding proteins 1A, 2X, and 2B in Streptococcus pneumoniae isolates for which 
amoxicillin MICs are higher than penicillin MICs. Antimicrob Agts Chem 2004;48:4020–22. 
33 
 
[103] Fojo T. Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions 
and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. 
Drug Resistance Updat 2007;10(1-2):59-67  
[104] Touchon M, Moura de Sousa J, Rocha E. Embracing the enemy: the diversification of 
microbial gene repertoires by phage mediated horizontal gene transfer. Curr Op Microbiol 
2017;38:66–73. 
[105] Zinder ND. Forty years ago: the discovery of bacterial transduction. Genetics 
1992;132:291–94. 
[106] Willetts N, Wilkins B. 1984 Processing of plasmid DNA during bacterial conjugation. 
Microbiol Rev 1984;48(1):24-41. 
[107] Kaiser AD, Hogness DS. The transformation of Escherichia coli with deoxyribonucleic 
acid isolated from bacteriophage lambda-dg. J Mol Biol. 1960;2:392–415. 
[108] Stewart GJ, Carlson CA. The biology of natural transformation. Annu Rev Microbiol. 
1986;40:211–235 
[109] Zeng X, Lin J. Beta-lactamase induction and cell wall metabolism in Gram-negative 
bacteria. Front Microbiol 2013;4:128 
[110] Khan AU, Maryam L, Zarrilli R. Structure, Genetics and Worldwide Spread of New Delhi 
Metallo-β-lactamase (NDM): a threat to public health. BMC Microbiol 2017;17(1):101 
[111] Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev 
1988;1:109–23 
[112] Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev 
2010;23(1):160–201. 




[114] Ambler RP. The structure of b-lactamases. Philo Trans R Soc Lond B Biol Sci 
1980;289:321–31. 
[115] Fisher JF, Meroueh SO, Mobashery S. Bacterial resistance to beta-lactam antibiotics: 
Compelling opportunism, compelling opportunity. Chem Rev 2005;105 395–424. 
[116] Jaurin B, Grundstrom T. AmpC cephalosporinase of Escherichia coli K-12 has a different 
evolutionary origin from that of b-lactamases of the penicillinase type. Proc Natl Acad Sci USA 
1981;78:4897–4901. 
[117] Ouellette M, Bissonnette L, Roy PH. Precise insertion of antibiotic resistance determinants 
into Tn21-like transposons: nucleotide sequence of the OXA-1 b-lactamase gene. Proc Natl Acad 
Sci USA 1987;84:7378–82  
[118] Llarrull LI, Tioni MF, Vila AJ. Metal content and localization during turnover in B. cereus 
metallo-beta-lactamase. J Am Chem Soc 2008;130:15842–51 
[119] Tioni MF, Llarrull LI, Poeylaut-Palena AA, Martí MA, Saggu M, Periyannan GR, Mata 
EG, Bennett B, Murgida DH, Vila AJ. Trapping and characterization of a reaction intermediate 
in carbapenem hydrolysis by B. cereus metallo-beta-lactamase. J Am Chem Soc 
2008;130:15852–63. 
[120] Palzkill T. Metallo-β-lactamase structure and function. Ann NY Acad Sci 
2012;1277(1):91–104.  
[121] Lim HM, Pene JJ, Shaw RW. Cloning, nucleotide sequence, and expression of the Bacillus 
cereus 5/B/6 beta-lactamase structural gene. J Bacteriol 1988;170:2873–78. 
[122] Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of 
buprenorphine: ceiling effects at high doses. Clin Pharm Therapeut 1994;55:569-80. 
[123] Laraki N, Franceschini N, Rossolini GM, Santucci P, Meunier C, de Pauw E, Amicosante 
G, Frere JM, Galleni M. Biochemical characterization of the Pseudomonas aeruginosa 101/1477 




[124] Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, Rossolini 
GM. Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene 
from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agts Chemo 1999;43:1584–90. 
[125] Galleni M, Lamotte-Brasseur J, Rossolini GM, Spencer J, Dideberg O, Frere JM, 
Amicosante G, Franceschini N, Bush K, Concha NO, Herzberg O, Livermore DM, Rasmussen 
BA, Rodrigues J, Saavedra MJ, Sutton B, Fabiane SM, Toney JH. Standard numbering scheme 
for class B beta-lactamases. Antimicrob Agts Chem 2001;45(3):660-3. 
[126] Concha NO, Janson CA, Rowling P, Pearson S, Cheever CA, Clarke BP, Lewis C, Galleni 
M, Frère JM, Payne DJ, Bateson JH, Abdel-Meguid SS. Crystal structure of the IMP-1 metallo -
beta lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate 
inhibitor: binding determinants of a potent, broad spectrum inhibitor. Biochem 2000;39:4288–98 
[127] Garcia-Saez I, Docquier JD, Rossolini GM, Dideberg O. The three-dimensional structure 
of VIM-2, a Zn-beta-lactamase from Pseudomonas aeruginosa in its reduced and oxidised form. 
J Mol Biol 2008;375:604–11. 
[128] Borra PS, Leiros HK, Spencer J, Leiros I, Walsh TR, Sundsfjord A, Samuelsen O. 
Structural and computational investigations of VIM-7: insights into the substrate specificity of 
vim metallo- beta-lactamases. J Mol Biol 2011;411:174–89. 
[129] King DT, Strynadka N. Crystal structure of New Delhi metallo-β-lactamase reveals 
molecular basis for antibiotic resistance. Prot Sci 2011;20:1484–91. 
[130] Kim Y, Tesar C, Mire J, Jedrzejczak R, Binkowski A, Babnigg G, Sacchettini J, 
Joachimiak A. Structure of apo- and monometalated forms of NDM 1—a highly potent 
carbapenem-hydrolyzing metallo-β-lactamase. PLoS One 2011;6:e24621.  
[131] Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing 
enterobacteriaceae. Emerg Infect Dis 2011;17(10):1791-8. 
[132] Navidinia M, Karimi A, Rahbar M, Fallah F and et al. Study Prevalence of verotoxigenic 
E. coli isolated from urinary tract infections (UTIs) in an Iranian children hospital. The open 
Microbiol J 2012;6:1-4. 
36 
 
[133] Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 
Characterization of a new metallo-β-lactamase gene, bla (NDM-1), and a novel erythromycin 
esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 
from India. Antimicrob Agts Chem 2009;53:5046–54. 
[134] Neu HC. Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit 
beta-lactamases. The Am J Med 1985;79(5):2–12. 
[135] Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. pp. 490, 
2006. ISBN 9783527607495. 
[136] English AR, Retsema JA, Girard AE, Lynch JE, Barth WE. CP-45,899, a -lactamase 
inhibitor that extends the antibacterial spectrum of -lactams: initial bacteriological 
characterization. Antimicrob Agnts Chem 1978;14:414–419. 
[137] Fisher J, Belasco JG, Charnas RL, Khosla S, Knowles, JR. Beta-lactamase inactivation by 
mechanism-based reagents. Philos Trans R Soc Lond B Biol Sci 1980;289:309–19. 
[138] Toussaint KA, Gallagher JC. β-Lactam/β-Lactamase Inhibitor Combinations. Ann 
Pharmacother 2014;49(1):86–98.  
[139] Higgens CE, Kastner RE. Streptomyces clavuligerus sp. nov., a β-Lactam antibiotic 
producer. Int J Syst Bacteriol 1971;21:326–31 
[140] Imtiaz U, Billings E, Knox JR, Manavathu EK, Lerner SA, Mobashery S. Inactivation of 
class A beta-lactamases by clavulanic acid: the role of arginine-244 in a proposed nonconcerted 
sequence of events. J Am Chem Soc 1993;115(11):4435–42.  
[141] Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of 
tazobactam with b-lactamases from all major structural classes. Antimicrob Agents Chemother 
1993;7:851–858 




[143] Bonomo RA, Rudin SA, Shlaes DM. Tazobactam is a potent inactivator of selected 
inhibitor-resistant class A -lactamases. FEMS Microbiol Lett 197;148:59–62. 
[144] Buynak JD. Understanding the longevity of the -lactam antibiotics and of antibiotic/-
lactamase inhibitor combinations. Biochem Pharmacol 2006;71:930–40. 
[145] Rafailidis PI, Ioannidou EN, Falagas ME. Ampicillin/Sulbactam Current Status in Severe 
Bacterial Infections. Drug 2007;67(13):1829–49.  
[146] Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 372 
Avibactam is a covalent, reversible, nonβ-lactam β-lactamase inhibitor. Proc Natl Acad Sci 
2012;109:11663–8. 
[147] Drawz SM, Papp-Wallace KM, Bonomo RA. New β-Lactamase inhibitors: a therapeutic 
renaissance in an MDR world. Antimicrob Agts Chem 2013;58(4):1835–46 
[148] Aszodi J, Fromentin C, Lampilas M, Rowlands DA. Aventis Pharma SA, assignee 
Heterocyclic compounds, which are active as inhibitors of β-lactamases. Jan 27, 2003. 
International Patent number PCT/FR2003/000243. 
[149] Coleman K. Diazabicyclooctanes (DBOs): a potent new class of non-beta-lactam beta-
lactamase inhibitors. Curr Opin Microbiol 2011;14:550–5. 
[150] Wang DY, Abboud MI, Markoulides MS, Brem J, Schofield CJ. The road to avibactam: 
the first clinically useful non-β-lactam working somewhat like a β-lactam. Fut Med Chem 
2016;8(10):1063–84. 
[151] King DT, Sobhanifar S, Strynadka NC. One ring to rule them all: current trends in 
combating bacterial resistance to the beta-lactams. Prot. Sci. 2016;4:787–803. 
[152] Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, 
Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, 
Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN. Discovery of a cyclic 
boronic acid beta-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J 
Med Chem 2015;9:3682–92. 
38 
 
[153] Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, Landman D. Activity 
of meropenem combined with RPX7009, a novel b-lactamase inhibitor, against gram-negative 
clinical isolates in New York City. Antimicrob Agts Chem 2015;59(8):4856–60. 
[154] Blizzard TA, Chen H, Kim S, Wu J, Bodner R, Gude C, Imbriglio J, Young K, Park YW, 
Ogawa A, Raghoobar S, Hairston N, Painter RE, Wisniewski D, Scapin G, Fitzgerald P, Sharma 
N, Lu J, Ha S, Hermes J, Hammond ML. Discovery of MK-7655, a b-lactamase inhibitor for 
combination with Primaxin. Bioorg Med Chem Lett 2014;24(3):780–5. 
[155] Mitchell S, Humphries RM. New and Novel Agents Targeting Resistant Gram-Negative 
Bacteria: A Review for the Clinical Microbiologist. Clin Microbiol Newslett 2018;40(18):147–
55. 
[156] Docquier J-D, Mangani S. An update on β-lactamase inhibitor discovery and development. 
Drug Resist Updat 2018;36:13–29 
[157] Payane DJ, Bateson JH, Gasson BC, Proctor D, Khushi T, Farmar TH, Tolson DA, Bell D, 
Skett PW, Marshall AC, Reid R, Ghosez L, Combret Y, Marchand-Brynaert J. Inhibition of 
metallo-beta-lactamases by a series of mercaptoacetic acid thiol ester derivatives. Antimicrob 
Agts Chem 1997;41:135–40.  
[158] Mollard C, Moali C, Papamicael C, Damblon C, Vessilier S, Amicosante G, Schofield CJ, 
Galleni M, Frere J-M, Roberts GCK. Thiomandelic acid, a broad-spectrum inhibitor of zinc_β-
Lactamases. J. Biol. Chem. 2001;276:45015–23.  
[159] Heinz U, Bauer R, Wommer S, Meyer-Klaucke W, Papamichaels C, Bateson J, Adolph 
HW. Coordination geometries of metal ions in D- or L-captopril-inhibited metallo-β-lactamases. 
J Biol Chem 2003;278:20659–66.  
[160] Faridoon, Hussein WM, Vella P, Islam NU, Ollis DL, Schenk G, McGeary RP. 3-
mercapto-1,2,4-triazoles and N-acylated thiosemicarbazides as metallo-β-lactamase inhibitors. 
Bioorg Med Chem Lett 2012;22(1):380-6 
[161] Bounanga S, Laws AP, Galleni M, Page MI. The mechanism of catalysis and the inhibition 
of the Bacillus cereus zinc-dependent β-lactamase. Biochem J 1998;331:703–11.  
39 
 
[163] Roll DM, Yang Y, Wildey MJ, Bush K, Lee MD. Inhibition of metallo-beta-lactamases by 
pyridine monothiocarboxylic acid analogs. J Antibiot 2010;63:255–7.  
[163] Vanthoeun K, Bunho T, Mitsuhashi R, Suzuki T, Kita M. Preparation and characterization 
of N,N-diacetatodithiocarbamato metal complexes with large negative charges, Inorg Chim Acta, 
2013;394:410. 
[164] Dunkel VC, San RHC, Seifried HE, Whittaker P. Genotoxicity of iron compounds in 
Salmonella typhimurium and L5178Y mouse lymphoma cells. Environ Mol Mutag 1999;33:28–
41 
[165] Bhattacharya A, Shukla RE, Auyang D, Dietrich KN, Bornschein R. Effect of succimer 
chelation therapy on postural balance and gait outcomes in children with early exposure to 
environmental lead. Neurotoxicol. 2007;28(3):686–95. 
[166] Lin-Tan DT, Lin JL, Yen TH, Chen KH, Huang YL. Long-term outcome of repeated lead 
chelation therapy in progressive non-diabetic chronic kidney diseases. Nephrol Dial. Transpl 
2007; 22(10):2924–31. 
[167] Aoki N, Ishii Y, Tateda K, Saga T, Kimura S, Kikuchi Y, Kobayashi T, Tanabe Y, 
Tsukada H, Gejyo F, Yamaguchi K. 2010. Efficacy of calcium-EDTA as an inhibitor for 
metallo-beta-lactamase in a mouse model of Pseudomonas aeruginosa pneumonia. Antimicrob 
Agts Chem 2010;54(11):4582–88. 
[168] Yoshizumi A, Ishii Y, Livermore DM, Woodford N, Kimura S, Saga T, Harada S, 
Yamaguchi K, Tateda K. Efficacies of calcium-EDTA in combination with imipenem in a 
murine model of sepsis caused by Escherichia coli with NDM-1 β-lactamase. J Infect Chem 
2013;19(5):992–5. 
[169] Quinn PJ, Carter ME, Markey PK, Carter GR. Enterobacteriaceae. In: Quinn PJ, Carter 
ME, Markey PK, Carter GR. (Eds), Clin Vet Microbiol pp.209-236, 1994.  Wolfe Publishing, 
London. 




[171] Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, Shrestha NK, Fraser 
TG, van Duin D. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae 
bloodstream infections. Diag Microbiol Infect Dis 2011;69:357–62. 
[172] Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of 
urinary tract infections due to multidrug-resistant organisms. Antimicrob Agts Chem 2012;56: 
5744–48. 
[173] Van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem resistant 
Enterobacteriaceae: a review of treatment and outcomes. Diag Microbiol Infect Dis 2013;75: 
115–20. 
[174] Hyle EP, Ferraro MJ, Silver M, Lee H, Hooper DC. Ertapenem-resistant 
Enterobacteriaceae: risk factors for acquisition and outcomes. Infect Ctrl Hosp Epidemiol 
2010;31:1242–9. 
[175] CDC. Centers for Disease Control and Prevention. Facility guidance for control of 
carbapenem-resistant Enterobacteriaceae (CRE), 2015b. CRE Toolkit www.cdc.gov 
[176] Van Duin D, Doi Y. The global epidemiology of carbapenemase-producing 
Enterobacteriaceae. Virul 2017;8(4):460–9.  
[177] Hu F, Zhu D, Wang F. CHINET 2014 surveillance of bacterial resistance in China. Chin J 
Infect Chem 2015;1:401–10. 
[178] Sekyere JO. Current state of resistance to antibiotics of last-resort in South Africa: a 
review from a public health perspective. Front Publ Hlth 2016;4:209.  
[179] Brink AJ, Coetzee J, Clay CG, Sithole S, Richards GA, Poirel L. et al. Emergence of New 
Delhi metallo-beta-lactamase (NDM-1) and Klebsiella pneumonia carbapenemase (KPC-2) in 
South Africa. J Clin Microbiol 2012;50:525–7.  
[180] Brink AJ, Coetzee J, Corcoran C, Clay CG, Hari-Makkan D, Jacobson RK, Richards GA, 
Feldman C, Nutt L, van Greune J, Deetlefs JD, Swart K, Devenish L, Poirel L, Nordmann P. 
Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South 
41 
 
Africa and evidence of in vivo selection of colistin resistance as a consequence of selective 
decontamination of the gastrointestinal tract. J. Clin. Microbiol. 2013;51:369–72.  
[181] Jacobson RK, Manesen MR, Moodley C, Smith M, Williams S, Nicol M, Bamford CM. 
Molecular characterisation and epidemiological investigation of an outbreak of blaOXA-181 
carbapenemase-producing isolates of Klebsiella pneumonia in South Africa. S Afr Med J 
2015;105:1030–5. 
[182] Smith SVJ. Molecular imaging with Copper-64. Inorg Biochem 2004;98: 1874−1901.   
[183] Boeyens JCA, Van der Merwe MJ. The Nonexistent Crystals of Macrocyclic Nickel(III). 
Structure of the Cobalt (III) Complex of 1,4,7-Triazacyclononane-N,N',N"-triacetate. Inorg 
Chem 1997;36:3779–80. 
[184] Clarke ET, Martell AE. Stabilities of trivalent metal ion complexes of the tetraacetate 
derivatives of 12-, 13- and 14-membered tetraazamacrocycles. Inorg Chim Acta 1991;190(1): 
37–46 
[185] Ebenhan T, Zeevaart JR, Venter JD, Govender T, Kruger GH, Jarvis NV, Sathekge MM. 
Preclinical evaluation of 68Ga-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-ubiquicidin 
as a radioligand for PET infection imaging. J Nucl Med 2014;55:308-14 
[186] Gasser G, Tjioe L, Graham B, Belousoff MJ, Juran, S, Walther M, Künstler J-U, 
Bergmann R, Stephan H, Spiccia L. Synthesis, copper (II) complexation, 64 Cu-labeling, and 
bioconjugation of a new bis(2-pyridylmethyl) derivative of 1,4,7-triazacyclononane. Bioconj 
Chem 2008;19:719–30. 
[187] Joshi T, Kubeil M, Nsubuga A, Singh G, Gasser G, Stephan H. Harnessing the 
Coordination Chemistry of 1,4,7-Triazacyclononane for Biomimicry and Radiopharmaceutical 
Applications. Chem Plus Chem 2018; 83(7):554–64. 
[188] Guillou A, Lima LMP, Roger M, Esteban-Gómez D, Delgado R, Platas-Iglesias C, Tripier 
R. 1,4,7-Triazacyclononane-Based Bifunctional Picolinate Ligands for Efficient Copper 
Complexation. European Journal of Inorganic Chemistry, 2017;(18):2435–43.  
42 
 
[189] Michel PJ, Yeh R, Chait RC, Kishony MR. Drug interactions modulate the potential for 
evolution of resistance. Proc Natl Acad Sci USA 2008;105(1491):8-23. 
[190] Kim S, Lieberman TD, Kishony R. Alternating antibiotic treatments constrain evolutionary 
paths to multidrug resistance. Proc Natl Acad Sci USA 2014;111. 
[191] Munck C, Gumpert HK, Wallin AIN, Wang HH, Sommer MO. Prediction of resistance 
development against drug combinations by collateral responses to component drugs. Sci Transl 
Med 2014;6(262):156. 
[192] Moellering RC. Antimicrobial synergism: an elusive concept. J Infect Dis 1979;140:639-
41 
[193] Pierren M, Tigges, M. Adjuvant strategies for potentiation of antibiotics to overcome 
antimicrobial resistance. Curr Opin Pharmacol 2012;12:551-5. 
[194] Berenbaum MC. A method for testing synergy with any number of agents. J Infect Dis 
1978;137:122–30.  
[195] Berenbaum MC. What is synergy? Pharmacol Rev 1989;41:93–141. 
[196] Horrevorts AM, de Ridder CM, Poot MC, de Jonge MJA, Degener JE, Djoljic-Danilovic 
G, Michel MF, Kerrebijn KF. Checkerboard titrations: the influence of the composition of serial 
dilutions of antibiotics on the fractional inhibitory concentration index and fractional bactericidal 
concentration index. J Antimicrob Chem 1987;19:119–125 
[197] Timurkaynak F, Can F, Azap OK. et al. In vitro activities of non-traditional antimicrobials 
alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and 
Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agts 2006;27:224-
8. 




[199] Mueller M, de la Pena A, Derendorf H. Issues in Pharmacokinetics and Pharmacodynamics 
of Anti-Infective Agents: Kill Curves versus MIC. Antimicrob Agts Chem 2014;48(2):369–77.  
[200] Ferro BE, van Ingen J, Wattenberg M, van Soolingen D, Mouton JW. Time-kill kinetics of 
antibiotics active against rapidly growing mycobacteria. J Antimicrob Chem 2014;70(3):811–17 
[201] Mouton JW, Punt N, Vinks AA. (2007). Concentration-effect relationship of ceftazidime 
explains why the time above the MIC is 40 percent for a static effect in vivo. Antimicrob Agts 
Chem 2007;51(9): 3449–51. 
[202] Beam TR, Gilbert DN, Kunin CM. General guidelines for the clinical evaluation of anti-
infective drug products. Clin Infect Dis 1992;15(Suppl. 1). 
[203] Beam TR, Gilbert DN, Kunin CM. The European Working Party (eds) 1993. European 
guidelines for the clinical evaluation of anti-infective drug products. Euro Soc Clin Microbiol 
Infect Dis. 
[204] Zak O. Usefulness and limitations of animal models in the study of opportunistic 
nonbacterial infections. In: Infections in Cancer Patients (ed. Klastersky, J.), pp. 25-45, 1982. 
Raven Press, New York. 
[205] O'Reilly T, Cleeland R, Squires EL. Evaluation of antimicrobials in experimental animal 
infection. In Antibiotics in Laboratory Medicine, 4th edn. (ed. Lorian, V.), pp. 604-765, 1996. 
Williams and Wilkins, Baltimore, MD 
[206] Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial 
dosing of mice and men. Clin Infect Dis 1998;26:1-10. 
[207] Craig WA, Gudmundsson S. The postantibiotic effect. In: Antibiotics in Laboratory 
Medicine, 4th ed, (ed. Lorian, V.), pp. 296-329, 1996. Williams and Wilkins, Baltimore, MD. 
[208] Eagle H, Fleischman R, Musselman AD. The bactericidal action of penicillin in vivo: the 




[209] Gerber AU, Craig WA, Brugger H-P, Feller C, Vastola AP, Brandel AP. Impact of dosing 
intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in 
granulocytopenic mice. J Infect Dis 1983;147:910-7. 
[210] Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig W.A. In vivo postantibiotic 
effect in a thigh infection in neutropenic mice. J Infect Dis 1988;157:287-98. 
[211] Hillenkamp F. et al. Matrix-assisted laser desorption/ionization mass spectrometry of 
biopolymers. Analyt Chem 1991;63:1193A-1203A. 
[212] Link AJ. et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotech 
1999;17:676-82. 
[213] Louris JN. et al. Instrumentation, applications, and energy deposition in quadrupole ion-
trap tandem mass spectrometry. Analyt Chem 1987;59:1677-1685 
[214] Wilm M. et al. Femtomole sequencing of proteins from polyacrylamide gels by nano-
electrospray mass spectrometry. Nat 1996;379:466-469. 
[215] Jia RZ. et al. Identification and classification of rhizobia by matrix-assisted laser 
desorption/ionization time- of-flight mass spectrometry. J Proteom Bioinform 2015;8:098-107. 
[216] Pomastowski P. et al. Evaluation of intact cell matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry for capillary electrophoresis detection of controlled bacterial 
clumping. J Anal Bioanal Tech 2015;S13:008 
[217] Narayan M. et al. Identification of novel CDC37 interacting proteins and pathways in 
human Alzheimer‘s disease brain tissue using mass spectrometry. J Data Mining Genom 
Proteom. 2016;7:193. 
[218] Chapman JR. Practical Organic Mass Spectrometry, 2nd Ed., 1993, Wiley, London. 




[220] Kieffer LJ, Dunn GH. Electron impact ionization cross-section data for atoms, atomic ions, 
and diatomic molecules: I. Experimental data. Rev Mod Phys 1966;38:1-35. 
[221] Märk TD, Dunn GH. Electron impact ionization. Springer Vienna. 2013;24-41. 
[222] Pitt JJ. Principles and applications of liquid chromatography-mass spectrometry in clinical 
biochemistry. The Clin Biochem Rev 2009;30:19-34. 
[223] Carroll DI. et al. Subpicogram detection system for gas phase analysis based upon 
atmospheric pressure ionization (API) mass spectrometry. Analyt Chem 1974;46:706-10. 
[224] Marchi I, Rudaz S, Veuthey J-L. Atmospheric pressure photoionization for coupling 
liquid-chromatography to mass spectrometry: a review. Talanta 2009;78:1-18. 
[225] Morris HR. et al. Fast atom bombardment: A new mass spectrometric method for peptide 
sequence analysis. Biochem Biophys Res. Comm. 1981;101:623-31. 
[226] Barber M. et al. Fast Atom Bombardment Mass Spectrometry. Analyt Chem 
1982;54:645A-657A. 
[227] Yamashita M, Fenn JB. Electrospray ion source. Another variation on the free-jet theme. 
The J Phys Chem 1984;88(20):4451–9.  
[228] Leonid VZ, Yaroslava GY, Tatiana EI, Tracy AS, Barbara JG. Molecular dynamics 
simulations of matrix-assisted laser desorption connections to experiment. Int J Mass Spectromet 
2003;226:85-106. 
[229] Stachniuk A, Fornal E. Food Anal. Methds 2016;9:1654 
[230] Lee MS, Kerns EH. (1999). LC/MS applications in drug development. Mass Spectromet 
Rev 1999;18 (3–4):187–279. 
[231] Wysocki VH, Resing KA, Zhang Q, Cheng GR, Zhang C. Mass spectrometry of peptides 
and proteins. Methds 2005;35(3):211–22.  
46 
 
[232] Gika HG, Theodoridis GA, Plumb, RS, Wilson ID. Current practice of liquid 
chromatography–mass spectrometry in metabolomics and metabonomics. J Pharm Biomed 
Analy 2014;87:12–25.  
[233] Stobiecki M, Skirycz A, Kerhoas L, Kachlicki P, Muth D, Einhorn J, Mueller-Roeber B. 
Profiling of phenolic glycosidic conjugates in leaves of Arabidopsis thaliana using LC/MS. 





In vitro and in vivo evaluation of metal chelating agents as potential metallo beta-lactamase 






















Catalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, Durban, 
South Africa. 
Running title: Potential MBL inhibitors against carbapenem resistant Enterobacteriaceae 
Corresponding authors: 
*Professor Tricia Naicker / *Dr Sooraj Bajinath 
Catalysis and Peptide Research Unit 
E-block, 6th floor, Room E1-06-016 
University of KwaZulu-Natal, Westville Campus, South Africa 
Offices: +27 31 260 81799 
Email address: Naickert1@ukzn.ac.za/ BaijnathS@ukzn.ac.za 
Highlights 
 This study presents the in vitro and in vivo activities of two metal chelators (NOTA and 
NO3PY) against carbapenem resistant Enterobacteriaceae.  
 Both chelators were able to return the activity of meropenem, resulting in MICs as low as 
0.06 mg/ml. 
 NO3PY showed poor bioavailability in pharmacokinetic experiments, therefore only 
NOTA was used for in vivo efficacy tests. 





Herein we compared the in vitro and in vivo activities of two metal chelators (NOTA and 
NO3PY) as potential metallo beta-lactamase inhibitors (MBLIs).  The minimum inhibitory 
concentration (µg/ml) of meropenem co-administered with metal chelators against meropenem 
resistant strains was determined. These resistant bacterial strains include; Escherichia coli NDM-
1, Klebsiella pneumoniae 449, Escherichia coli IMP-1 and Enterobacter cloacae NDM-1. Also, 
the time kill kinetics over a 24-hour period was evaluated. Both MBLIs restored the efficacy of 
meropenem against all bacteria tested. Bonferroni‘s pairwise comparison test showed significant 
differences between 8* MIC and 16* MIC when compared to the meropenem control in E. coli 
NDM-1 for NOTA and only 16 *MIC for NO3PY. Overall, there were no major differences in 
the in vitro efficacy of the MBLIs.  A validated liquid chromatography- mass spectrometric 
method (LC–MS) for the quantification of meropenem and each chelator, in mouse plasma was 
developed. Forty-eight healthy male Balb/c mice were divided into two groups; 
meropenem+NO3PY group and meropenem+NOTA group. Both groups received intraperitoneal 
doses at 10 mg/kg of meropenem and the MBLIs. NO3PY showed poor bioavailability at the 
selected doses. NOTA was bioavailable and its in vivo efficacy was determined. The co-
administration of meropenem and NOTA (100 mg/kg each) in a murine thigh infection model 
brought about a significant decrease in the colony forming unit counts of K. pneumoniae 449 
over an 8-hour period. The findings suggest that NOTA holds strong potential for use as a 






Metallo beta-lactamase, Chelating agents, Enterobacteriaceae, Infection modeling 
2.1. Introduction 
Beta-lactams are the most widely prescribed class of antibiotics throughout the world [1,2]. Its 
broad-spectrum activity makes it suitable for the treatment of a wide range of infections caused 
by gram positive and gram-negative bacteria [3]. Carbapenems are beta-lactam drugs that are 
regarded as the last line of defense against infections caused by resistant bacteria [4,5]. 
Unfortunately, resistance to carbapenems is on the increase [6]. Infections caused by carbapenem 
resistant Enterobacteriaceae (CREs) have contributed significantly to the morbidity and 
mortality rate globally [7]. The main resistance mechanism employed by Enterobacteriaceae 
against carbapenems is the production of various forms of hydrolyzing enzymes, called beta-
lactamases [8]. 
Beta-lactamases are able to hydrolyze the antibiotic beta-lactam ring through a series of reactions 
which ultimately lead to the destruction of the antibiotic [9]. The beta-lactamase enzymes are 
either categorized as serine beta-lactamases or metallo beta-lactamases according to their 
structural configuration and mode of action [10]. The former has serine at its active site while the 
latter has zinc [10]. The synthesis of beta-lactamase inhibitors capable of overcoming resistance 
to beta-lactam drugs, is a thriving area of research [11]. Serine beta-lactamases have been 
successfully inhibited by beta-lactamase inhibitors which are clinically available, these include, 
clavulanic acid, avibactam, sulbactam and tazobactam [12]. The mechanism of action of metallo 
beta-lactamase inhibitors is to covalently bind to zinc within the beta lactamase enzyme, as a 
result the metallo beta-lactamase enzyme is truncated and the efficacy of the beta-lactam drug is 
restored [13]. Attempts have been made to synthesize metal-chelating agents that can function as 
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metallo beta-lactamase inhibitors by chelating the zinc in the active site of beta-lactamase 
enzyme [14,15].  
Bifunctional chelating agents (BFCAs) are routinely used in radio-imaging and 
radiopharmaceuticals [16-18]. They are well known for their ability to bind small molecules and 











 among others [21-28]. BFCAs have two moieties, one is a strong metal binding 
unit used in complexing a radionuclide of interest while the other binds a carrier biomolecule 
(e.g antibodies, peptides) that serves to transport the complexed radionuclides to the target site in 
vivo [29-30]. Examples of BFCAs include, 1,4,7-triazacyclononane-1,4,7 triacetic acid (NOTA), 
1,4,7,10 tetraazacyclododecane (DOTA), diethylenetri-aminepentaacetic acid (DTPA) etc. 
[29,31-32]. The strong affinity of BFCAs for metal ions have been exploited for their ability to 
bind zinc which is essential for metallo beta-lactamase action [10, 14-15].  
Reports by Somboro et al. suggested that the co-administration of NOTA and meropenem 
(Supplementary file 1), against metallo beta-lactamase producing CREs was successful in 
producing a bacteriostatic effect in vitro [33]. However, this study neither investigated the time-
kill kinetics nor the in vivo efficacy of this combination. 1,4,7- tris (2-picolinyl)-1,4,7-
triazacyclononane (NO3PY), a BFCA has so far only been used for radiochemistry [34]. This 
compound was synthesized in our laboratory and used as a potential MBLI for this study. Using 
time kill kinetics , the activities of NOTA and NO3PY (Supplementary file 1) when co-
administered with meropenem against MBL- producing CREs (E. coli NDM-1, K. pneumoniae 
449, E. cloacae NDM-1 and E. coli IMP-1) were evaluated. This was to determine the rate at 
which these compounds at different concentration reduce the growth of  MBL- producing CREs 
over a period of time.  We went further to investigate the in vivo pharmacokinetics and efficacy 
51 
 
of these inhibitors in combination with meropenem. This study, is to the best of our knowledge 
the first time that a BFCA, NO3PY will be tested for metallo beta-lactamase inhibition when co-
administered with meropenem against a panel of metallo-beta lactamase producing bacteria. This 
study is also the first to investigate the in vivo pharmacokinetics and efficacy of NOTA as a 
metallo beta-lactamase inhibitor.  
 
2.2. Methods 
2.2.1. Bacterial source 
Metallo beta-lactamase producers belonging to the family of Enterobaceriaceae were purchased 
from Patrice Nordmann at the Institut National de la Santé et de la Recherche Médicale (U914), 
Paris, France [35]. The bacterial strains used were; Escherichia coli NDM-1, Klebsiella 
pneumoniae 449, Escherichia coli IMP-1and Enterobacter cloacae NDM-1. These bacterial 
strains were selected based on their varying degrees of susceptibility to meropenem. Bacterial 
stock solutions were preserved in Trypticase soy agar and glass beads (4mm) at -80
o
C. 
Escherichia coli ATCC 25922 was used as the control. 
2.2.2. Antibiotics and inhibitors  
Meropenem was obtained from Sigma-Aldrich (Schnelldorf, Germany) and NOTA from 
Macrocyclics, Texas, United States of America. NO3PY was made available by the synthesis 
group of Catalysis and Peptide Research Unit, University of KwaZulu Natal, South Africa. The 
structure was confirmed by nuclear magnetic resonance (NMR) as reported in literature [34]. 
Distilled water was used for preparing meropenem and NOTA stock solutions while phosphate 
buffered saline was used for NO3PY. Meropenem stock solution was stored at -80ºC.  
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2.2.3 Susceptibility testing 
The broth microdilution method, according to the Clinical and Laboratory Standards Institute, 
2014 [36], was used to determine the susceptibility profile of meropenem alone and in 
combination with NO3PY and NOTA using the checkerboard method [37]. Mueller–Hinton 
broth (MHB) was used as the growth medium for the study. A 0.5 McFarland standard for each 
bacterial suspension was used. The experiment was conducted in ninety-six well microtitre 
plates. Thereafter, the plates were incubated at 35ºC for 24 h. The minimum inhibitory 
concentration was recorded at the antibiotic-inhibitor drug concentration that showed no visible 
growth in the presence of the resazurin dye. The test was conducted at three independent times to 
confirm results (Table 1).  
2.2.4. Time kill assay 
An initial inoculum density of 10
7
cfu/ml of test organism was added to Eppendorf tubes 
containing MHB and meropenem at graded concentrations of MIC, 1*MIC, 2*MIC, 4*MIC, 
8*MIC and 16*MIC. The inhibitors were added at a fixed concentration of 8 µg/ml. Meropenem 
and growth control groups were included. For the former control group, the exact MIC of 
meropenem alone against the test organism was used (32 µg/ml for E. cloacae NDM-1 and 16 
µg/ml for E. coli IMP-1) except for K. pneumoniae 449 and E. coli NDM-1 where only clinically 
achievable concentrations were used (32 µg/ml). Aliquots of 100ul in duplicate were removed 
for colony counts at hours of 0, 2, 4, 6, 8, 10 and 24. Viable counts were determined by the serial 
dilution method and plated on Mueller Hinton agar (MHA). MHA- plates were incubated at 35ºC 
for 24 h and plate counts were done after 24 h of incubation. Antimicrobial agents were 
considered bactericidal at the lowest concentration, which reduced the original inoculum by ≥3 
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log10 CFU/ml (99.9%). Values for each time point is generated from the mean±SD values of the 
duplicate CFU/ml count from a single experiment (Figures 1-4).   
2.3 Pharmacokinetic study 
Male Balb/c mice (average weight 26 ± 2 g) were obtained from Biomedical Resource Unit 
(UKZN, Durban, South Africa) and housed under standard conditions, in an air-conditioned 
room with a 12 h light/dark cycle and were given ad libitum access to food and water. Animals 
were given a 10 mg/kg.b.w dose of meropenem and 10 mg/kg.b.w of each inhibitor 
intraperitoneally. The animals were euthanized at 0, 5, 15, 30, 45, 60, 90, and 120 min post 
dosing (n=3 per time point), this allowed for a plasma time-concentration curve of each drug to 
be generated. At the time of termination, approximately 0.5 - 0.7 ml of blood was collected into 
heparinized micro-tubes for plasma-drug concentration analyses. Blood plasma was separated by 
centrifugation at 10000 rpm for 10 minutes and was analysed using liquid chromatography mass 
spectrometry (LC-MS).  
 
2.3.1 Sample preparation for LC-MS/MS analysis 
During sample preparation, 100 μl of the biological sample was spiked with 20 μl of IS and 
vortexed for 1 min, after which 880 μl of MeOH was added to extract target analytes and to 
induce the precipitation of proteins. The mixture was then vortexed for 1 min, followed by 
centrifugation at 13 000 g for 15 min at 4ºC. The supernatants were filtered through an SPE 
cartridge [DSC-18 (50mg)] suitable for the sample. The filtrate was then collected into auto-
sampler vials and vortexed briefly, before injecting into the LC-MS/MS system. The calibration 
curve was constructed, following the same procedure. 
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The liquid chromatography (LC) system was an Agilent technology 1100 (Agilent, Germany) 
series coupled to a Bruker QTOF-II (Bruker Daltonics, Bremen, Germany) with electrospray 
ionization (ESI) source and a time-of-flight mass spectrometry (TOF-MS) mass analyzer (Bruker 
Daltonics, Bremen, Germany). Chromatographic separation was achieved using an Ascentis 
Express RP-Amide column (5cm x 2.1 mm; 2.7 μm particle size) (Supelco, Sigma-Aldrich, 
Germany). Mobile phase A was millipore water (0.1% v/v FA) and mobile phase B was 
methanol (0.1% v/v FA), with a flow rate of 0.4 ml/min and column compartment set to room 
temperature. A gradient method was used to achieve chromatographic separation increasing from 
70% A to 30% B. The injection volume was 5µl and the total run time was 10 mins. The MS 
acquisition parameters were: positive ion polarity; end plate offset was 500 V; capillary voltage -
5000 V; nebulizer - 1.8 bar; dry gas flow rate - 8 l/min; dry heater temperature - 180 ºC; scan 
range was from m/z 100 - 500; collision cell radio-frequency was 500 Vpp; collision energies 
were 1eV for NO3PY, NOTA, meropenem and ampicillin (internal standard). Data Analysis 4.0 
SP 5 (Bruker Daltonics) was used to further process the data (Figure 5). 
 
2.4 In vivo murine thigh infection model  
A thigh infection protocol was performed as described by Michail et al. [38]. Briefly, six-week 
old, pathogen free-specific, male Bagg inbred albino c-strain (BALB/c) mice weighing 20-25 g 
(n=40), were rendered neutropenic (neutrophils <100/mm
3
) by administration with 
cyclophosphamide, intraperitoneally (IP) at 4 days (150 mg/kg) and 1 day (100 mg/kg) before 





CFU/ml. This procedure was done two hours before the treatment with meropenem + NOTA 
(100 mg/kg.b.w each) combination, commenced. The mice were randomly separated into two 
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groups, the infected control and the treated group. Mice were humanely euthanized, by halothane 
overdose, at 2h, 4h, 6h and 8h post treatment. The left thigh muscle was then aseptically 
removed and homogenized in 5ml of phosphate buffered saline (PBS). Homogenates were 
serially diluted eight times and plated onto antibiotic-free Mueller-Hinton agar plates for each 
dilution, and incubated at 35
o
C for 24h. Following the incubation period, the plates were 
assessed for growth and quantitatively enumerated using colony forming units (CFU), the titer 
was then expressed as log10 CFU/thigh muscle (Figure 6). 
2.5 Statistical analyses 
Experimental data generated from the time-kill kinetic study were analysed using GraphPad 
Prism version 5.0 (GraphPad Inc., San Diego, CA, USA). The bacterial density was represented 
using log10 cfu/ml units and was plotted against time in hours for each bacterium. The kill rate 
was determined at different time intervals using a linear regression model to find the slope for 
each transformed concentration. Thereafter, a non-linear regression analysis (dose-response) was 
used to determine the sigmoidal model for the evaluation of the pharmacodynamic relationship 
between the antibiotic concentration and bacterial growth or death. The 50% inhibitory 
concentration, Hill‘s slope and r2 were also determined. A comparative analysis of the kill rate of 
each of the beta-lactamase inhibitor in combination with meropenem was assessed using the two-
way analysis of variance (ANOVA). Bonferroni‘s pairwise comparison test was used to compare 
the effectiveness of growth control, meropenem control and kill rate of both beta-lactamase 




2.6.1. Susceptibility test results  
The minimum inhibitory concentration (MIC) of meropenem alone and in combination with 
NOTA and NO3PY against carbapenem resistant Enterobacteriaceae was determined. The 
results (Table 1) show that E. coli NDM-1, K. pneumoniae 449, E. coli IMP-1 and E. cloacae 
NDM-1 were highly resistant to meropenem. Excellent activity was achieved by NO3PY in 
restoring the efficacy of meropenem at a concentration as low as 0.06 µg/ml for all organisms 
except K. pneumoniae 449 for which the MIC was 0.125µg/ml. Also, meropenem when co-
administered with NOTA produced inhibition at a concentration as low as 0.06 µg/ml for all 
organisms except E. coli NDM-1 and K. pneumoniae 449 for which the MIC was 0.125 µg/ml. 
 
 
Table 2. 1: The MICs of meropenem only and in combination with NOTA and NO3PY 
(n=3)   
 
Organism 
                      Minimum Inhibitory Concentration (µg/ml) 
 
                 [a] 
1
                         [a+ b] 
2
                        [a+ c]
3
 
Escherichia coli NDM-1                 128                           0.06+4                        0.125+4 
Klebsiella pneumonia 449                 128                           0.125+4                       0.125+4 
Escherichia coli IMP-1                  16                            0.06+4                         0.06+4 
Enterobacter cloacae NDM-1                 32                             0.06+4                          0.06+4 
 
 a = concentration of meropenem (µg/ml) 
 b = concentration of NO3PY (µg/ml) 
 c = concentration of NOTA (µg/ml) 
 1 = concentration of meropenem alone that resulted in inhibition 
 2= concentration of meropenem and NO3PY that resulted in inhibition 
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  3= concentration of meropenem and NOTA that resulted in inhibition 
 
2.6.2. Test group comparison of the resistant bacteria 
E. coli NDM1 with NO3PY showed (Figure 1A) there was significant increase (P < 0.05) in 
colony forming unit (cfu) count of growth control compared to other groups, while Bonferroni's 
analysis revealed significant difference (P < 0.05) in efficacy of 16*MIC (1+8) compared to the 
meropenem control. No significant difference between other MICs with the comparison test 
(Figure 1A).  E. coli NDM1 with NOTA shows a significant increase (P < 0.05) in the colony 
forming unit (cfu) count of growth control compared with other groups (Figure 1B). The 
Bonferroni‘s comparison multiple test revealed significant difference (P < 0.05) in the efficacy 
of 8*MIC (0.5+8) and 16*MIC (1+8) compared to the meropenem control (Figure 1B). Other 
MICs reveal no significant difference in the comparison tests (Figure 1B). For other organisms 
(K. pneumoniae- 449, E. coli IMP-1 and E. cloacae NDM-1), the growth control compared to 
other groups with both metallo beta-lactamase inhibitors showed there was significant increase 
(P < 0.05) in cfu count. However, there was no statistically significant difference between other 

















































































Figure 2. 1: E. coli NDM-1 exposed to meropenem co-administered with NO3PY (A) and NOTA (B) at different MICs. NO3PY 
indicates significant difference (P < 0.05) between meropenem control and 8*MIC (1+8). NOTA shows significance (P < 0.05) 
between meropenem control and 8*MIC (1+8) and 16*MIC (2+8). Symbol a indicates significant increase in the rate of kill as 










































































Figure 2. 2: K. pneumoniae-449 exposed to meropenem co-administered with NO3PY (A) and NOTA (B) at different MICs. No 









































































Figure 2. 3: E. coli IMP-1 exposed to meropenem co-administered with NO3PY (A) and NOTA (B) at different MICs. No 








































































Figure 2. 4: E. cloacae NDM-1 exposed to meropenem co-administered with NO3PY (A) and NOTA (B) at different MICs. No 
significant difference (P < 0.05) between the treatment groups. Mean values of duplicate cfu/ml count are plotted
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2.6.3. Comparison between NO3PY and NOTA against resistant bacteria 
Drug efficacy against the resistant bacteria shows that there was no significant difference 
between the two inhibitors against two of the resistant E. coli NDM-1 and K. pneumoniae- 449. 
However, for E. coli IMP-1, there was a significant increase in the efficacy of NO3PY compared 
to NOTA. E. cloacae NDM-1 also showed significant difference between the two inhibitors 
(Table 2). Generally, the mean difference shows that NO3PY is slightly more effective than 
NOTA, although these differences were not significant 
Table 2. 2: Association between NO3PY and NOTA inhibitors against metallo beta-
lactamase producing CREs 
Resistant organisms Mean square F P value 
E. coli NDM-1 7.9630 1.9940 P = 0.1956 
K. Pneumoniae -449 0.3571 0.1573 P = 0.7021 
E. coli IMP-1 3.5080 6.2610 P = 0.0368* 
E. cloacae NDM-1 3.5750 6.249 P = 0.0370* 
 
The efficacy (reduction of the cfu per time) of the two inhibitors when co-administered with 
meropenem against metallo beta-lactamase producing organisms. It is calculated from the log10 
of the colony forming unit counts. *represents P < 0.05.  
2.6.4. IC50 evaluation 
Notably, there were significant differences in the IC50 of inhibitors tested against K. pneumonia-
449 and E. coli IMP-1 (Table 3). The lowest IC50 dose for NO3PY was against E. coli IMP-1 
while that of NOTA was against E. cloacae NDM-1.  It was also observed that the NO3PY 




Table 2 3: Non-linear regression model fitted to time-kill assay data 
  Meropenem MIC 2*MIC 4*MIC 8*MIC 16*MIC 
E. coli NDM-1 (NO3PY) IC50 (µg/ml) 15.87 8.408 8.437 8.587 8.403 8.809 
 Hill slope 9.004 -216.4 -36.13 -18.24 -14.01 -14.01 
 R
2
 0.93 0.17 0.37 0.57 0.57 0.56 
E. coli NDM-1 (NOTA) IC50 (µg/ml) 15.87 8.626 8.676 8.465 8.558 8.483 
 Hill slope 9.004 -31.19 -36.47 -118.5 -30.87 -18.73 
 R
2
 0.93 0.48 0.57 0.76 0.63 0.73 
K. pneumonia-449 (NO3PY) IC50 (µg/ml) 21.26 8.990 7.515 7.966 7.337 5.105
a
 
 Hill slope 74.65 -156.8 -6.693 -7.278 -3.882 -4.188 
 R
2
 0.78 0.68 0.71 0.81 0.90 0.97 
K. pneumonia-449 (NOTA) IC50 (µg/ml) 21.26 8.497 4.564 8.802 8.294 9.723
b
 
 Hill slope 74.65 -41.30 -10.17 -44.56 -14.58 -15.68 
 R
2
 0.78 0.68 0.70 0.73 0.84 0.42 




 0.1386 0.1293 0.0056
a
 
 Hill slope -3.550 -0.3319 -0.5994 -2.160 -0.9984 -0.4433 
 R
2
 0.99 0.85 0.82 0.75 0.73 0.75 









 Hill slope -3.550 -0.3705 -1.475 -1.814 -1.727 -1.476 
 R
2
 0.99 0.92 0.98 0.99 0.99 0.99 
E. cloacae NDM-1 (NO3PY) IC50 (µg/ml) 0.0850 0.3279 0.0010 0.026 0.035 0.014 
 Hill slope -1.546 -2.490 -0.290 -0.987 -1.830 -3.159 
 R
2
 0.80 0.91 0.83 0.87 0.87 0.89 
E. cloacae NDM-1 (NOTA) IC50 (µg/ml) 0.0850 0.2422 0.0120 0.008 0.007 0.028 
 Hill slope -1.546 -2.231 -0.7139 -0.602 -1.561 -0.985 
 R
2
 0.80 0.96 0.87 0.82 0.81 0.81 
 
 
This is the IC50 value of meropenem and the inhibitors at different MICs against metallo beta-lactamase producing organisms. a 







Figure 2 5: Concentrations of meropenem in plasma, following a single 10 mg kg−1 intraperitoneal dose of meropenem 
NO3PY and NOTA (data are represented as means ± SD, n= 3). NO3PY was below the limit of detection (10 ngml
-1
) and could 
not be quantified. NOTA was above the limit of detection (10 ngml
-1






































Figure 2. 6: In vivo efficacy of NOTA when co-administered with meropenem in a murine thigh infection model (data are 
represented as means ± SD, n= 3). Student T-test revealed that there is significant difference (P = 0.0031) between the infected 






























2.7. Discussion   
This study demonstrates how the co-administration of the two beta-lactamase inhibitors with 
meropenem was able to re-sensitize metallo-beta lactamase producing Enterobacteriaceae to 
carbapenems in vitro. Previously, it has been reported that NOTA was able to restore the efficacy 
of meropenem against E. coli NDM-1 and E. cloacae NDM-1 [33]. In this study we went further 
to investigate the other metallo beta-lactamase producing Enterobacteriaceae and to investigate 
the time kill kinetics of this approach. NO3PY, from the minimum inhibitory concentrations 
demonstrated its ability to chelate the zinc moiety present at the active site of the metallo-beta-
lactamase in vitro thus leading to its inactivation and the eventual restoration of the potency of 
meropenem against CREs (Table 1).  
Meropenem alone did not show a high kill effect on E. coli NDM-1, K. pneumoniae 449, E. coli 
IMP-1 and E. cloacae NDM-1 with time as regrowth was observed before 24 h, this could be 
attributed to the presence of resistant mutants.  The beta-lactamase inhibitor individual analysis 
indicated that NO3PY exhibited the highest killing effect on E. coli IMP-1 while NOTA had the 
highest on E. cloacae NDM-1 with time (Table 2). Though, there were noticeable differences in 
the killing activity of both inhibitors on other resistant bacteria, however, this was not 
statistically significant. The action of meropenem is time–dependent [40,41], and this work 
reveals that meropenem alone appeared highly and rapidly bacteriostatic in the early logarithmic 
phase of growth till 4 h in E. coli NDM-1 before a growth relapse was observed after 6 h. 
Meanwhile, the MIC 2*MIC, 4*MIC, 8*MIC and 16*MIC extend their killing rate until 10 h 
before a weaker effect was noticed (Figures 1A and 1B), thus not only did the inhibitors restored 
the efficacy of meropenem, they also prolonged its duration of action. This prolonged action was 
also observed for K. pnemoniae-449 which maintained relatively bacteriostatic activity until the 
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10 h and 24 h for meropenem and all the MICs respectively. Greater number of colony-forming 
units were observed for meropenem by the 24 h (Figures 2A and 2B). The E. coli IMP-1 was 
susceptible to meropenem when co-administered with both inhibitors showing an impressive 
bactericidal effect on the organism (Figures 3A and 3B); the same was observed in E. cloacae 
NDM-1 (Fig 4A and 4B). The half maximal inhibitory concentration (IC50) evaluation suggest an 
overall effectiveness of beta-lactamase inhibitors against most of the resistant organisms (Table 
3).  
NOTA was below the limit of quantification in the PK study (Figure 5), but it was detected, 
therefore we have performed the in vivo tests of NOTA at a much higher dose (100 mg.kg.b.w). 
At this concentration the chelator was able to restore the potency of meropenem by significantly 
reducing the colony forming unit count of K. P 449 when compared to the infected control 
(Figure 6).  
Furthermore, the restoration of the potency of meropenem by NO3PY might only be limited to in 
vitro analysis. This is due to the poor bioavailability of the inhibitor in vivo as it was also below 
the limit of detection (Figure 5). A possible explanation for this is that the inhibitor‘s strong 
affinity for metal ions may have resulted in it being bound to serum cations. For the use of 
BFCAs for radiotherapy, a complexed metal ion is introduced into the biological system in 
conjugation with a vector, allowing for transport to the target site [42]. It should be noted that the 
chemical properties of a complex (a metal ion complexed by a chelator) is different from that of 
the free metal ion or the ligand, it is these differences that may enhance the bioavailability of the 
chelator in vivo thus making them desirable and applicable as radiopharmaceuticals [43].  
Herein, we introduced a free chelator into the biological system. To improve its in vivo 
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bioavailability as an MBLI, it is logical that other factors such as linking it to a carrier 
biomolecule be considered in its development for further clinical applications.  
2.8. Conclusions 
The administration of NOTA and NO3PY in vitro was able to restore the efficacy of meropenem 
against K. pneumoniae 449, E. coli NDM-1, E. coli IMP-8 and E. cloacae NDM-1.  From the 
time kill kinetics, the chelators showed similar trends in their bacterial kill rate however, NO3PY 
demonstrated a slightly better efficacy than NOTA though not significant. In the in vivo 
pharmacokinetics study, NO3PY had poor availability when compared to NOTA. The 
derivatization of NO3PY with a carrier molecule may lead to the enhancement of its 
bioavailability. The potency of meropenem when co-administered with NOTA was restored in a 
murine thigh infection model. Further preclinical work like in vitro and in vivo cytotoxicity tests, 
post beta-lactamase inhibitor effects among others are recommended for NOTA to further 
ascertain its suitability as a potential clinical metallo beta-lactamase inhibitor. It is also 
recommended that the affinity, stoichiometry and thermodynamics between these metal chelators 





evaluated using isothermal titration calorimetry. Further modifications of these MBLIs are 
ongoing in our laboratory. 
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There is a growing global concern due to the increasing development of antibiotic resistance 
mechanisms in pathogenic bacteria, especially those mediated by beta-lactamases. Genes 
encoding metallo beta-lactamases are spreading rapidly, thus causing serious outbreaks which 
have very few treatment options. It is therefore imperative and urgent to find possible ways of 
combatting this scourge, by identifying agents that can be co- administered with carbapenems to 
inhibit the activity of these enzymes. If the activity of metallo beta-lactamase is inhibited, it will 
be unable to compete with carbapenems for the penicillin binding protein receptor in the 
bacterium. Thus, the bacterium will be resensitized to the effects of carbapenems, leading to the 
eradication of the infection. 
This study has focused on the evaluation of the in vitro and in vivo activity of metal chelating 
agents NO3PY and NOTA as potential metallo beta-lactamase inhibitors. The chelators are 
ligands normally used in binding nuclides/ metal ions for radioimaging and therapy.   The 
checkerboard MIC results revealed that both chelators were able to restore the efficacy of 
meropenem in vitro. This lends credence to the ability of the inhibitors to chelate zinc ions 
present at the active site of metallo beta-lactamase enzymes. The time kill kinetics also showed 
that both compounds were able to significantly extend the killing time of meropenem. A 
sensitive LC-MS method was developed to detect NOTA in plasma, but it was below the limit of 
quantification whereas NO3PY was undetectable.  NOTA was also able to potentiate the effects 
of meropenem in vivo which was evident by the significant decrease of the colony forming unit 
count of Klebsiella pneumoniae 449 when compared to infected control in a murine thigh 
infection model. This suggests that NOTA holds a strong potential of being a clinically available 
metallo beta-lactamase inhibitor.  
A possible way of improving the bioavailability of these chelators in the biological system is to 
either derivatize the structure in such a way that it will preferentially bind to the zinc molecule in 
the active site of the metallo beta-lactamase enzymes or if they can be targeted directly to the site 
of infection either by encapsulating in microspheres, nanoparticles, liposomes or linking it to a 
biological vector.  All these approaches will prevent the chelators from binding to stray metal 
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ions in the body. Thus, their overall bioavailabity will increase and by extension their potency in 
vivo. As NOTA restored the potency of meropenem in a murine thigh infection, this might just 
be the first step in unveiling the answer to the scourge of infections mediated by MBL-producing 
CREs.  It is therefore recommended that further in vitro and in vivo cytotoxicity assays should be 
carried out. The possibility of the MBLIs in restoring the potency of carbapenems in vivo should 
be tested further in primates (monkeys, apes etc) before it can be subjected to clinical trials in 
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